Synthesis method of chiral (–)-cephalotaxine and its intermediates and analogs

The synthesis steps of chiral (–)-cephalotaxine were simplified by using a rhodium-catalyzed (2+3) cyclization reaction of asymmetric enamides with enol diazonium acetate, solving the problems of waste of chemical reagents and cumbersome steps in the existing technology, and realizing efficient and low-cost large-scale production.

CN116425760BActive Publication Date: 2024-11-26LANZHOU UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310188141.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-02
Publication Date
2024-11-26
Estimated Expiration
2043-03-02

AI Technical Summary

Technical Problem

Existing technologies for synthesizing chiral (–)-cephalotaxine suffer from significant waste of chemical reagents and cumbersome synthesis steps, making it difficult to achieve efficient and low-cost large-scale production.

Method used

A rhodium-catalyzed (2+3) cyclization reaction of an asymmetric enamide with an enol diazonium acetate was used to synthesize chiral (–)-cephalotaxine intermediates and their analogues via a nine-step reaction. This simplified the operation steps and reduced byproducts, while the metal-catalyzed asymmetric reaction reduced enantiomer waste.

Benefits of technology

A concise and efficient synthesis of chiral (–)-cephalotaxine intermediates and their analogues has been achieved, reducing synthesis costs, making them suitable for industrial production, and improving the yield of the target product and chiral economy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004106457150000011
    Figure BDA0004106457150000011
  • Figure BDA0004106457150000021
    Figure BDA0004106457150000021
  • Figure BDA0004106457150000031
    Figure BDA0004106457150000031
Patent Text Reader

Abstract

The invention discloses a method for synthesizing chiral (–)-cephalotaxine and its intermediates and analogs. The method of the invention uses aryl alcohol compounds as starting materials, obtains key intermediates and its analogs through metal-catalyzed asymmetric (2+3) cyclization reaction, and obtains chiral (–)-cephalotaxine and its analogs through nine steps of reaction and two column chromatography. The synthetic method is easy to operate, has a high reaction yield, and is expected to be applied to industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of asymmetric catalytic organic synthesis, and in particular relates to an asymmetric catalytic synthesis method of chiral (-)-cephalotaxine and its intermediates and analogs. Background Art

[0002] Cephalotaxine, also known as Cephalotaxine in English, is a crystalline alkaloid isolated from the branches and leaves of Torreya grandis and Cephalotaxus chinensis by Puadler et al. (Paudler, WW et al. J. Org. Chem. 1963, 28, 2194). In 1974, Powell et al. (Powell, RG et al. J. Org. Chem. 1974, 39, 1269) esterified Cephalotaxine with bromobenzoic acid, and determined the absolute stereo configuration of Cephalotaxine from the X-ray crystal diffraction of the obtained ester: 3S, 4S, 5R. Its molecular structure and absolute configuration are shown in the following formula:

[0003]

[0004] Many ester-base derivatives of cephalotaxine have significant antitumor activity (Powell, RG et al. J. Pharm. Sci. 1972, 61, 1227). Since the 1970s, my country has used cephalotaxine for the treatment of cancer and acute myeloid leukemia and other related diseases, and has achieved remarkable results. It has been included in the 1990 edition of the Chinese Pharmacopoeia (Pharmacopoeia Committee of Ministry of Health Chinese Pharmacopoeia, 1990 Edition II, People's Health Pub House, Beijing, 1990, pp. 588-590 (in Chinese)). In 2012, the U.S. Food and Drug Administration (FDA) approved the use of homoharringtonine for the treatment of chronic myeloid leukemia.

[0005] At present, Cephalotaxine is mainly isolated and extracted from Cephalotaxus truncatus plants, but due to the limited resources of Cephalotaxus truncatus plants and the extremely low content of ester alkaloids with anti-cancer activity, it is far from meeting clinical needs. The chemical synthesis of Cephalotaxine is a scientific and feasible way to solve the problem of sustainable development of such resources, which has very important practical significance.

[0006] Since the 1970s, scientists have been committed to the artificial synthesis of cephalotaxine, but the structural complexity and particularity of cephalotaxine (three consecutive chiral centers) have brought great difficulties to its artificial synthesis. The synthesis of cephalotaxine is mainly divided into the synthesis of racemic cephalotaxine and the synthesis of chiral cephalotaxine. So far, there are mainly three methods for preparing pure chiral (–)-cephalotaxine by chemical synthesis internationally (for some representative review articles, see: (a) Pérard-Viret, J.; Quteishat, L.; Alsalim, R.; Royer, J.; Dumas, F. The Alkaloids: Chemistry and Biology 2017, 78, 205; (b) Li, W.-DZ et al. Chin. J. Org. Chem. 2017, 37, 1885):

[0007] (1) Based on the chiral resolution method, the racemic target product is directly resolved by chemical resolution reagents or biological enzymes, or the racemic key intermediate is resolved and then the target product ((–)-cephalotaxine) is obtained by chemical transformation. This is a traditional method for preparing optically pure natural products ((a) Zhong, S.-B. et al. Chin. J. Med. Chem. 1994, 4, 84 (Chinese); (b) Nagasaka, T. et al. Tetrahedron: Asymmetry 1997, 8, 191; (c) El Bialy, S.A.A. et al. Med. Chem. Res. 2002, 11, 293; (d) Mariano, P.S. et al. Tetrahedron 2006, 62, 7266; ​​(e) Stoltz, B.M. et al. J. Org. Chem. 2007, 72, 7352; (f) Renaud, P. et al. Helv. Chim. Acta 2012, 95, 2502; (g) Robin, JP et al. WO 2015162217; (h) Beaudry, CM et al. Angew. Chem. Int. Ed. 2019, 58, 6752).

[0008] The method for obtaining (–)-cephalotaxine based on the chiral resolution method is as follows:

[0009]

[0010] (2) Synthesis of (–)-cephalotaxine based on “chiral substrate and chiral reagent”

[0011] Starting from "chiral substrates" such as D-proline, D-ribose, D-(+)-diethyl tartrate, (2R,3R)-butanediol-derived chiral substrates and R-phenylethylamine-derived chiral substrates, (-)-cephalotaxine was synthesized ((a) Mori, M. et al. J. Org. Chem. 1995, 60, 115. (b) Ikeda, M. et al. Chem. Pharm. Bull. 1999, 47, 983. (c) Hayes, CJ et al. Org. Lett. 2008, 10, 3045. (d) Hayes yes, CJ et al. J.Org.Chem.2008,73,8045.(e) Kim, S. et al. J.Org.Chem.2019,84,8080.(f) Gin, DY et al. J.Am.Chem.Soc.2006,128,10370.(g) Ishibashi, H. et al. Org.Lett.2008,10,4129.(h) Li, W.-DZ et al. Chin.J.Org.Chem.2017,37,1885.)

[0012] Starting from "chiral reagents" such as S-naphthylethylamine and S-tert-butylsulfenamide, (-)-cephalotaxine was synthesized ((i) Royer, J. et al. J. Org. Chem. 2004, 69, 3087. (j) Marguerit, M. et al. Eur. J. Org. Chem. 2015, 8003. (k) Jiang, B. et al. CN 109776506A.).

[0013] The method for obtaining (–)-cephalotaxine based on “chiral substrate, chiral reagent” is as follows:

[0014]

[0015] The above two synthesis techniques for synthesizing (–)-cephalotaxine by chiral resolution and metered chiral induction (chiral raw materials, chiral reagents) will cause a huge waste of chemical reagents, racemic target products and intermediate substances.

[0016] (3) Synthesis of (–)-cephalotaxine with “asymmetric reaction catalyzed by metal or organic small molecules” as the key chiral induction step ((a) Tietze, LF et al. J. Am. Chem. Soc. 1999, 121, 10264. (b) Renaud, P. et al. Helv. Chim. Acta 2012, 95, 2502. (c) Tu, Y.-Q. et al. Chem. Asian J. 2012, 7, 894. (d) Li, W.-DZ et al. Org. Lett. 2018, 20, 1050.).

[0017] The method for obtaining (–)-cephalotaxine based on asymmetric reactions catalyzed by metal or organic small molecules is as follows:

[0018] Summary of the invention

[0019] The invention provides a novel method for synthesizing chiral (–)-cephalotaxine and intermediates and analogs thereof. The novel method has a simple synthesis route and high synthesis efficiency, and chiral (–)-cephalotaxine intermediates and analogs with diverse structures can be synthesized by the novel method.

[0020] A method for synthesizing chiral (–)-cephalotaxine and its intermediates and analogs comprises the following steps:

[0021] Step (A): firstly synthesizing an ene amide compound of formula (7);

[0022] Step (B): then reacting the enamide compound of formula (7) with the enol diazoacetate compound of formula (8) to obtain the cephalotaxine intermediate of formula (9) and its analogs;

[0023] Then, the decarboxylation reaction of step (C), the oxidation reaction of step (D) and the amide reduction and methanol removal reaction of step (E) are sequentially carried out from the cephalotaxine intermediate and its analogs of formula (9) to obtain chiral (–)-cephalotaxine and its analogs; the structure of the chiral (–)-cephalotaxine and its analogs is shown in formula (12):

[0024]

[0025] Wherein, in step (B), in a solvent, under the action of a catalyst, the enamide compound of formula (7) and the enol diazoacetate compound of formula (8) are reacted as follows:

[0026]

[0027] Wherein, n is 0 or 1; X can be carbon, nitrogen, oxygen, or sulfur;

[0028] Among them, R 1 , R 2 , R 3 and R 4 The following groups may be the same or different and are each independently selected from the following groups: hydrogen, amino, hydroxyl, mercapto, cyano, nitro, halogen, trihalomethyl, benzyl, benzenesulfonyl, p-toluenesulfonyl, methanesulfonyl, tert-butyldimethylsilyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldiphenylsilyl, dimethylphenylsilyl, C6-C14 Aryl or heteroaryl, C3-C9 cycloalkyl, C2-C6 alkynyl, C2-C6 alkenyl, C1-C4 alkyloxy C1-C4 alkyl, C1-C4 alkylthio C1-C4 alkyl, C1-C6 acyloxy C1-C4 alkyl, C1-C6 acyl C1-C4 alkyl; unsubstituted, singly substituted or polysubstituted, straight or branched, saturated or unsaturated C1-C 18 Alkyl, unsubstituted, singly or polysubstituted, straight-chain or branched, saturated or unsaturated, C1-C 18 Alkoxy, unsubstituted, singly or polysubstituted, straight-chain or branched, saturated or unsaturated, C1-C 18 Acyloxy, unsubstituted, singly or polysubstituted, straight-chain or branched, saturated or unsaturated, C1-C 18 Alkoxyacyl, unsubstituted, singly or polysubstituted, straight-chain or branched, saturated or unsaturated, C1-C 18 Acyl, unsubstituted, singly or polysubstituted, straight-chain or branched, saturated or unsaturated, C1-C 18 Alkylamino, C1-C 18 is a non-substituted, singly substituted or polysubstituted, straight-chain or branched, saturated or unsaturated di-(C1-C 18 ) alkylamino, unsubstituted, singly substituted or polysubstituted, straight chain or branched, saturated or unsaturated C1-C 18 Alkylthio; wherein the substituted substituent is selected from: amino, hydroxyl, mercapto, cyano, nitro, halogen or trihalomethyl, and the halogen refers to fluorine, chlorine, bromine or iodine;

[0029] Or, R 1 ,R 2 ,R 3 and R 4 is the adjacent group (R 1 / R 2 ,R 2 / R 1 ,R 2 / R 3 ,R 3 / R 2 ,R 3 / R 4 ,R 4 / R 3 ) exists in a state of being an all-carbocyclic or heterocyclic ring, and the all-carbocyclic or heterocyclic ring includes, but is not limited to, the following:

[0030]

[0031] Among them, R 6 , R 7 and R 8Each independently represents a C1-C4 alkyl group, a C1-C4 alkoxy group, a C6-C 14 Aryl or halogenated C1-C4 alkyl, wherein the C1-C4 alkyl is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, the C1-C4 alkoxy is selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy, the C6-C 14 The aryl group is selected from phenyl, and the halogenated C1-C4 alkyl group is selected from chloromethyl; wherein, is selected from trimethylsilyl, triethylsilyl, phenyldimethylsilyl, ethyldimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diethylmethylsilyl, triisopropylsilyl or chloromethyldimethylsilyl;

[0032] Among them, R 9 It can be C1-C4 alkyl, C6-C 14 Aryl, C7-C 15 Arylmethylene or halogenated C1-C4 alkyl; the C1-C4 alkyl is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, the C6-C 14 The aryl group is selected from phenyl, the C7-C 15 The arylmethylene group is selected from benzyl, and the halogenated C1-C4 alkyl group is selected from chloromethyl.

[0033] In one embodiment of the method of the present invention, in step (B), the solvent is selected from one or more of aromatic solvents, ester solvents, ether solvents, ketone solvents, alkane solvents and halogenated solvents, but is not limited thereto.

[0034] In a further embodiment of the method of the present invention, in step (B), the aromatic hydrocarbon solvent is selected from toluene, o-xylene, m-xylene, p-xylene or mesitylene, but not limited thereto; the ester solvent is selected from ethyl acetate, but not limited thereto; the ether solvent is selected from methyl tert-butyl ether, but not limited thereto; the ketone solvent is selected from acetone, but not limited thereto; the alkane solvent is selected from n-hexane or cyclohexane, but not limited thereto; the halogenated solvent is selected from 1,2-dichloroethane or chlorobenzene, but not limited thereto.

[0035] In a further embodiment of the method of the present invention, in step (B), the amount of the solvent used can be a conventional amount in the art. Preferably, the volume molar ratio of the solvent to the enamide compound of formula (7) is 1 L / mol-10 L / mol, for example: 3.6 L / mol.

[0036] In one embodiment of the method of the present invention, in step (B), the catalyst is a catalyst for catalyzing the generation of a chiral substance (hereinafter referred to as a chiral catalyst), and the chiral catalyst is selected from Rh2(S-PTA)4, Rh2(S-PTV)4, Rh2(S-PTPA)4, Rh2(S-PTPG)4, Rh2(S-PTTL)4, Rh2(S-PTAD)4, Rh2(S-TCPTTL)4, Rh2(S-BPTTL)4, Rh2(S-NTTL)4, Rh2(S-DOSP )4, Rh2(S-MSP)4, Rh2(S-MEPY)4, Rh2(R-BTPUCP)4; more preferably Rh2(S-PTTL)4 or Rh2(S-PTAD)4; and / or in step (B) of the synthesis method of the present invention, the molar ratio of the catalyst to the olefin amide compound of formula (7) is 0.001-0.05, preferably 0.002-0.02, for example: 0.004; and / or in step (B) of the synthesis method of the present invention, the reaction temperature is -30°C-50°C, preferably 0°C.

[0037] In one embodiment of the method of the present invention, in step (B), the reaction may further include post-treatment operations. For example, after the reaction is completed, petroleum ether is added and filtered to obtain a compound of formula (9).

[0038] In one embodiment of the method of the present invention, in step (C), in a solvent, in the presence of a halide metal salt and water, the cephalosporin intermediate of formula (9) and its analogs are subjected to a decarboxylation reaction as shown below to obtain the cephalosporin intermediate of formula (10) and its analogs;

[0039]

[0040] Among them, n, X, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 The meaning is the same as described above.

[0041] In one embodiment of the method of the present invention, in step (C), the solvent is selected from one or more of aromatic hydrocarbon solvents, ester solvents, ether solvents, ketone solvents, halogenated solvents, dimethyl sulfoxide solvents and N,N-dimethylformamide solvents, but is not limited thereto.

[0042] In a further embodiment of the method of the present invention, in step (C), the aromatic hydrocarbon solvent is selected from toluene, but not limited thereto; the ester solvent is selected from ethyl acetate, but not limited thereto; the ether solvent is selected from ethylene glycol dimethyl ether, but not limited thereto; the ketone solvent is selected from acetone, but not limited thereto; the halogenated solvent is selected from chlorobenzene, but not limited thereto.

[0043] In one embodiment of the method of the present invention, in step (C), the amount of the solvent used can be a conventional amount in the art. The volume molar ratio of the solvent to the cephalotaxine intermediate of formula (9) and its analogs is 1 L / mol-10 L / mol, preferably 2 L / mol-5 L / mol, for example: 3.5 L / mol;

[0044] In one embodiment of the method of the present invention, in step (C), the metal halide salt is selected from lithium chloride, sodium chloride, potassium chloride, lithium bromide, sodium bromide, potassium bromide, lithium iodide, sodium iodide or potassium iodide, but is not limited thereto; more preferably sodium bromide. The amount of the metal halide salt can be the conventional amount in the art, and preferably the molar ratio of the metal halide salt to the amount of the cephalotaxine intermediate of formula (9) and its analogues is 1.0-5.0, preferably 2.0-4.0, for example: 3.0.

[0045] In one embodiment of the method of the present invention, in step (C), the molar ratio of water to the cephalotaxine intermediate of formula (9) and its analogs is 1.0-5.0, preferably 1.5-3.5, such as 2.0.

[0046] In one embodiment of the process of the present invention, in step (C), the reaction temperature is 70°C-120°C, preferably 100°C.

[0047] In one embodiment of the method of the present invention, in step (C), the reaction may further include a post-treatment operation; the post-treatment operation is a conventional post-treatment operation of this type of reaction, preferably carried out as follows: after the reaction is completed, water is added to quench the reaction, and dichloromethane is used to extract to obtain an extract rich in the cephalosine intermediate and its analogues of formula (10), and then the extract is freed from the solvent (for example, by distillation under reduced pressure to remove the solvent) to obtain a crude product of the cephalosine intermediate and its analogues of formula (10), and then the obtained crude product is recrystallized to obtain the cephalosine intermediate and its analogues of formula (10).

[0048] In one embodiment of the method of the present invention, in step (D), in a solvent, in the presence of an oxidant and a base, the cephalosporin intermediate of formula (10) and its analogs are subjected to an oxidation reaction as shown below to obtain the cephalosporin intermediate of formula (11) and its analogs;

[0049]

[0050] Wherein, Me represents a methyl group; n, X, R 1 , R 2 , R 3 and R 4 The meaning is the same as described above.

[0051] In one embodiment of the method of the present invention, in step (D), i.e., in the synthesis of the cephalotaxine intermediate of formula (11) and its analogs, the solvent is selected from conventional solvents for such reactions in the art. The solvent is selected from one or more of methanol and / or ether solvents, nitrile solvents, ester solvents, and halogenated solvents, but is not limited thereto.

[0052] In a further embodiment of the method of the present invention, in step (D), the ether solvent is selected from tetrahydrofuran, but not limited thereto; the nitrile solvent is selected from acetonitrile, but not limited thereto; the ester solvent is selected from ethyl acetate, but not limited thereto; the chlorinated solvent is selected from dichloromethane or chloroform, but not limited thereto. The amount of the solvent may be the conventional amount used in the art for such reactions. The volume molar ratio of the solvent to the cephalotaxine intermediate of formula (10) and its analogs is 1 L / mol-10 L / mol, preferably 1 L / mol-5 L / mol, for example: 1.5 L / mol.

[0053] In the synthesis method of the present invention, in step (D), that is, in the synthesis process of the cephalosine intermediate and its analogues of formula (11), the high-valent iodine is selected from iodobenzene acetate, iodobenzene trifluoroacetate, iodobenzoylbenzene, 2-iodobenzoic acid, 5-chloro-2-iodobenzoic acid, 5-methoxy-2-iodobenzoic acid, 5-nitro-2-iodobenzoic acid or 4,5-dimethoxy-2-iodobenzoic acid, and is more preferably selected from 2-iodobenzoic acid; the molar ratio of the high-valent iodine to the cephalosine intermediate and its analogues of formula (10) is 1.0-2.0, preferably 1.1-1.5, for example: 1.2.

[0054] In a further embodiment of the method of the present invention, in step (D), the base is a common base used in the art for such reactions. The base is selected from potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, potassium phosphate, preferably potassium carbonate or potassium hydroxide; the molar ratio of the base to the cephalotaxine intermediate of formula (10) and its analogues is 1.0-5.0, preferably 2.0-4.5, for example: 3.0.

[0055] In one embodiment of the method of the present invention, in step (D), i.e., in the synthesis of the cephalotaxine intermediate of formula (11) and its analogs, the reaction temperature is 0°C-40°C, preferably 20°C-40°C, for example 25°C.

[0056] In one embodiment of the method of the present invention, in step (D), the reaction may further include post-treatment; the post-treatment is a conventional post-treatment operation of such reactions, comprising the following steps: after the reaction is completed, water is added to quench the reaction, the cephalosine intermediate of formula (11) and its analogues are extracted with dichloromethane, and the solvent is removed, for example, by vacuum distillation to obtain a crude product of the cephalosine intermediate of formula (11) and its analogues. The obtained crude product is purified by column chromatography to obtain the cephalosine intermediate of formula (11) and its analogues.

[0057] In one embodiment of the method of the present invention, in step (E), in tetrahydrofuran solvent, in the presence of a catalyst and silane, the amide in the cephalosporin intermediate of formula (11) and its analogs are reduced by reaction at room temperature, then p-toluenesulfonic acid is added and heated to reflux, and methanol is removed to obtain chiral (-)-cephalosporin of formula (12) and its analogs;

[0058]

[0059] In one embodiment of the method of the present invention, in step (E), the volume molar ratio of tetrahydrofuran to the cephalotaxine intermediate of formula (11) and its analogs is 1 L / mol-10 L / mol, preferably 2 L / mol-5 L / mol, for example: 2.5 L / mol.

[0060] In one embodiment of the method of the present invention, in step (E), the catalyst is preferably RhH(CO)(PPh3)3, Karstedt catalyst, Vaska catalyst, H2PtCl6·6H2O, Ti(O i Pr)4, Mo(CO)6, NiCl2(dme) or RuHCl(CO)(PPh3)3, more preferably RhH(CO)(PPh3)3; the molar ratio of the amount of the catalyst to the amount of the cephalotaxine intermediate of formula (11) and its analogues is 0.005-0.2, more preferably 0.01-0.05, for example: 0.01.

[0061] In one embodiment of the method of the present invention, in step (E), the silane is selected from 1,1,3,3-tetramethyldisiloxane (TMDS), polymethylhydrogensiloxane (PMHS), diethylsilane, triethylsilane, phenylsilane, diphenylsilane, diphenylmethylsilane or triethoxysilane, preferably phenylsilane; and / or the molar ratio of the silane to the cephalotaxine intermediate of formula (11) and its analogues is 1.0-5.0, preferably 1.5-3.0, for example: 2.5.

[0062] In one embodiment of the method of the present invention, in step (E), the molar ratio of p-toluenesulfonic acid to the cephalosporin intermediate of formula (11) and its analogs is 1.1.

[0063] In one embodiment of the method of the present invention, in step (A), the aromatic alcohol compound of formula (1) is used as the initial raw material to react and synthesize the compound of formula (2).

[0064]

[0065] In one embodiment of the method of the present invention, in step (A), in a solvent, under the action of a base, a compound of formula (2) and a compound of formula (3) are reacted as shown below to obtain a compound of formula (4);

[0066]

[0067] Among them, n, X, R 1 , R 2 , R 3 and R 4 The meaning is the same as described above.

[0068] Wherein, R is a leaving group, which may be a conventional leaving group in the art, preferably a halogen or a sulfonate group; the halogen is preferably chlorine, bromine or iodine, more preferably chlorine; the sulfonate group is preferably a methanesulfonate group, a p-toluenesulfonate group, a benzenesulfonate group or a trifluoromethanesulfonate group, more preferably a p-toluenesulfonate group.

[0069] Among them, R 5 is an alcohol protecting group, preferably a benzyl group, a silyl group, or an acyl group; the silyl group is preferably a tert-butyldimethylsilyl group, a triethylsilyl group, a methyldiphenylsilyl group, a triisopropylsilyl group, a triphenylsilyl group, a dimethylphenylsilyl group, a triethoxysilyl group, a tert-butyldiphenylsilyl group, and more preferably a tert-butyldimethylsilyl group; the acyl group is preferably an acetyl group or a benzoyl group.

[0070] In one embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (4), the solvent may be a conventional solvent for such reactions in the art. The solvent is selected from one or more of aromatic hydrocarbon solvents, ester solvents, ether solvents and halogenated solvents, but is not limited thereto.

[0071] In a further embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (4), the aromatic hydrocarbon solvent is selected from toluene, xylene or trimethylbenzene, but not limited thereto; the ester solvent is selected from ethyl acetate, but not limited thereto; the ether solvent is selected from ethylene glycol dimethyl ether, but not limited thereto; the chlorinated solvent is selected from 1,2-dichloroethane, but not limited thereto.

[0072] In a further embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (4), the amount of the solvent used can be a conventional amount used in the art for such reactions. The volume molar ratio of the solvent to the compound of formula (2) is 1 L / mol-10 L / mol, preferably 2 L / mol-5 L / mol, for example: 2 L / mol.

[0073] In one embodiment of the inventive method, in step (A), during the synthesis of the compound of formula (4), the base is a common base used in the art for such reactions. The base is selected from sodium hydride, potassium hydride, potassium tert-butoxide, sodium tert-butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide or potassium hexamethyldisilazide, more preferably sodium hydride.

[0074] In one embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (4), the amount of the base used can be the conventional amount used in the art for such reactions. The molar ratio of the compound of basic formula (2) is 1.0-2.0, preferably 1.2-1.5, for example: 1.5.

[0075] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (4), the reaction temperature is 50°C-120°C, preferably 80°C-120°C, for example: 100°C.

[0076] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (4), the reaction may further include post-treatment; the post-treatment method is a conventional post-treatment method for such reactions, preferably comprising the following steps: after the reaction is completed, water is added to quench the reaction, dichloromethane is extracted, the solvent is removed (for example, reduced pressure distillation), and the obtained crude product is washed with petroleum ether to obtain the compound of formula (4).

[0077] In one embodiment of the method of the present invention, in step (A), the method for synthesizing the enamide compound of formula (7) may further include the following steps: removing R from the compound of formula (4) in a solvent 5 Protecting group to obtain a compound of formula (5);

[0078]

[0079] Among them, n, X, R 1 , R 2 , R 3 , R 4 and R 5 The meaning is the same as described above.

[0080] In one embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (5), the solvent may be a conventional solvent for such reactions in the art. The solvent is selected from one or more of an ether solvent, a nitrile solvent, an alcohol solvent, an ester solvent or a halogenated solvent, but is not limited thereto.

[0081] In a further embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (5), the ether solvent is selected from tetrahydrofuran, but not limited thereto; the nitrile solvent is selected from acetonitrile, but not limited thereto; the alcohol solvent is selected from methanol, but not limited thereto; the ester solvent is selected from ethyl acetate, but not limited thereto; the chlorinated solvent is selected from dichloromethane or chloroform, but not limited thereto.

[0082] In a further embodiment of the method of the present invention, in step (A), during the synthesis of the compound of formula (5), the amount of the solvent used can be a conventional amount used in the art for such reactions. The volume molar ratio of the solvent to the compound of formula (4) is 1 L / mol-10 L / mol, preferably 1 L / mol-5 L / mol, for example: 2 L / mol.

[0083] In one embodiment of the method of the present invention, in step (A), in the synthesis method of the compound of formula (5), R 5 The reagent used for the protecting group depends on the type of protecting group; when R 5 When it is benzyl, Pd / C (Pd content is 5% or 10%), H2 and methanol are preferably used as removal conditions (hydrogenation to remove benzyl is a common organic chemical reaction, usually carried out under a hydrogen atmosphere; Pd / C means palladium carbon, which mainly plays the role of activating hydrogen. This method is a conventional method for removing benzyl in chemical reactions.); wherein the preferred reagent dosage and temperature are a mass ratio of Pd / C (for example: Pd content is 5%) to the compound of formula (4) of 0.1, hydrogen at 1 atm, room temperature reaction, and the preferred volume molar ratio of solvent methanol to the compound is 2 L / mol. When R 5 When it is silicon-based, preferably hydrofluoric acid, fluorosilicic acid, triethylamine trihydrofluoride, tetrabutylammonium fluoride hydrate, potassium hydrogen fluoride and ammonium fluoride are used as the removal reagent, and tetrahydrofuran or acetonitrile is used as the solvent, more preferably triethylamine trihydrofluoride is used as the removal reagent, and tetrahydrofuran is used as the solvent, wherein the preferred reagent dosage and temperature are that the molar ratio of triethylamine trihydrofluoride to the compound of formula (4) is 0.5, the reaction temperature is 25-65°C, for example 35-65°C or 55-65°C, such as 60°C, and the preferred volume molar ratio of the solvent to the compound is 2L / mol. When R 5When it is an acyl group, potassium carbonate and methanol are preferably used as removal conditions, wherein the preferred reagent dosage and temperature are that the molar ratio of potassium carbonate to the compound of formula (4) is 2.0, the reaction is carried out at room temperature, and the preferred volume molar ratio of the solvent methanol to the compound is 2L / mol.

[0084] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (5), the reaction temperature is 25°C-80°C, preferably 40°C-80°C, for example: 60°C.

[0085] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (5), the reaction may further include post-treatment; the post-treatment method is a conventional post-treatment method for such reactions, preferably comprising the following steps: after the reaction is completed, water is added to quench the reaction, filtering, washing the filter cake with petroleum ether, and washing with water to obtain the compound of formula (5).

[0086] In one embodiment of the method of the present invention, in step (A), the method for synthesizing the enamide compound of formula (7) may further include the following steps: oxidizing the compound of formula (5) in a solvent under the action of an oxidant to obtain a compound of formula (6);

[0087]

[0088] Where n, X, R 1 , R 2 , R 3 and R 4 The meaning is the same as described above.

[0089] In one embodiment of the method of the present invention, in step (A), in the synthesis method of the compound of formula (6), the solvent may be a conventional solvent for such reactions in the art. The solvent is selected from dichloromethane, 1,2-dichloroethane, chloroform, ethyl acetate, dimethyl sulfoxide or acetonitrile, but is not limited thereto. The amount of the solvent may be a conventional amount for such reactions in the art. Preferably, the volume molar ratio of the solvent to the compound of formula (5) is 5L / mol-15L / mol, preferably 5L / mol-10L / mol, for example: 10L / mol.

[0090] In a further embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (6), the oxidant is selected from 2-iodoacylbenzoic acid (IBX), Dess-Martin periodinane (DMP), pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), Swern periodinane, Pfitzner & Moffatt periodinane, Parrikh & Doering periodinane or Albright & Goldman periodinane, preferably selected from 2-iodoacylbenzoic acid.

[0091] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (6), the reaction temperature depends on the oxidant: when the oxidant used is IBX, DMP, PCC, PDC, the reaction temperature is room temperature to 50°C; when the oxidant used is Swern oxidant, Pfitzner & Moffatt oxidant, Parrikh & Doering oxidant or Albright & Goldman oxidant, the reaction temperature is -78°C.

[0092] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the compound of formula (6), the reaction may further include post-treatment; the post-treatment method is a conventional post-treatment method for such reactions, preferably comprising the following steps: after the reaction is completed, water is added to quench the reaction, ethyl acetate is extracted, and the solvent is removed (for example, reduced pressure distillation) to obtain the compound of formula (6).

[0093] In one embodiment of the method of the present invention, in step (A), the method for synthesizing the enamide compound of formula (7) may further include the following steps: subjecting the compound of formula (6) to a ring-closing reaction as shown below in the presence of a solvent and a Lewis acid to obtain the enamide compound of formula (7):

[0094]

[0095] In one embodiment of the method of the present invention, in step (A), during the synthesis of the enamide compound of formula (7), the solvent may be a conventional solvent for such reactions in the art; the amount of the solvent may be a conventional amount for such reactions in the art, and the volume molar ratio of the solvent to the compound of formula (6) is 1 L / mol-10 L / mol, preferably 2 L / mol-8 L / mol, for example: 5 L / mol.

[0096] In a further embodiment of the method of the present invention, in step (A), during the synthesis of the enamide compound of formula (7), the solvent is selected from one or more of halogenated solvents, nitro solvents, aromatic solvents, ester solvents, and ether solvents, but not limited thereto. The chlorinated solvent is selected from dichloromethane or 1,2-dichloroethane, but not limited thereto; the nitro solvent is selected from nitromethane, but not limited thereto; the aromatic solvent is selected from toluene, but not limited thereto; the ester solvent is selected from ethyl acetate, but not limited thereto; the ether solvent is selected from tetrahydrofuran, but not limited thereto.

[0097] In one embodiment of the method of the present invention, in step (A), during the synthesis of the enamide compound of formula (7), the Lewis acid may be a common Lewis acid used in the art for such reactions, preferably, the Lewis acid is selected from boron trifluoride etherate, tin tetrachloride, aluminum trichloride, indium trichloride, ferric chloride, indium tribromide, bismuth trichloride or cerium trichloride; more preferably indium trichloride, aluminum trichloride or tin tetrachloride, but not limited thereto. The amount of the Lewis acid may be a conventional amount used in the art for such reactions, and the molar ratio of the Lewis acid to the compound of formula (6) is 1.0-5.0, preferably 1.0-2.5, for example: 1.2.

[0098] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the enamide compound of formula (7), the reaction temperature is 0°C-100°C, preferably 30°C-70°C, for example: 50°C.

[0099] In one embodiment of the method of the present invention, in step (A), in the method for synthesizing the enamide compound of formula (7), the reaction may further include post-treatment; the post-treatment method is a conventional post-treatment method for such reactions, preferably comprising the following steps: after the reaction is completed, water or a saturated sodium potassium tartrate (a composite salt formed by sodium tartrate and potassium tartrate) solution is added to quench the reaction, dichloromethane is extracted, and the solvent is removed (for example, vacuum distillation) to obtain a crude product, which is recrystallized to obtain the enamide compound of formula (7).

[0100] In the method of the present invention, the overall synthetic route for preparing chiral (-)-cephalotaxine and its intermediates and analogs from the enamide compound of formula (7) is as follows:

[0101]

[0102] Among them, n, X, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8,R 9 and Me have the same meanings as described above.

[0103] In the method of the present invention, the general route for preparing the enamide compound of formula (7) is as follows:

[0104]

[0105] Where n, X, R, R 1 , R 2 , R 3 , R 4 and R 5 The meaning is the same as described above.

[0106] Another aspect of the present invention provides a chiral (-)-cephalotaxine and its intermediates and analogs, wherein the structure of the chiral (-)-cephalotaxine intermediates and its analogs is any one of formula (9), formula (10) and formula (11):

[0107]

[0108] The structure of chiral (–)-cephalotaxine and its analogs is shown in formula (12):

[0109]

[0110] Where n, X, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 The meaning expressed is the same as that described in claim 1.

[0111] In the present invention, the term "equivalent" is generally used to describe the ratio of the amount of two substances when they interact. For example, 19 mmol of compound 5k is used to react with 22.8 mmol of compound IBX. Taking 5k as the basis, the molar amount of IBX used is 1.2 times that of 5k, that is, the equivalent is 1.2.

[0112] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred condition examples of the present invention.

[0113] Compared with the existing chiral synthesis method, the method of the present invention has the following advantages:

[0114] 1. The present invention proposes to construct the key C4 and C5 chiral centers in the molecular structure of Cephalotaxine by rhodium-catalyzed (2+3) annulation reaction of asymmetric enamide and enol diazoacetate, wherein the C4 and C5 chiral centers are marked with "*" as follows:

[0115]

[0116] This reaction can be used to synthesize the tetracyclic skeleton of the chiral cephalotaxine intermediate and its analogs shown in formula (9) in a simple, efficient and scalable manner, thereby providing a new route for the continued synthesis of chiral cephalotaxine intermediate analogs with diverse structures, and also providing a new method for the efficient synthesis of chiral (–)-cephalotaxine and its analogs.

[0117] 2. The method for synthesizing cephalotaxine of the present invention uses aryl alcohol compounds as starting materials, undergoes nine steps of reaction (1→2; 2→4; 4→5; 5→6; 6→7; 7→9; 9→10; 10→11; 11→12), and two column chromatography steps (10→11, 11→12) to obtain optically pure chiral (–)-cephalotaxine and its analogs. The method has a small number of steps, which greatly simplifies the experimental operation; and overall, there are few by-products in the method process (the intermediates of most chemical transformation steps do not need to be separated by column chromatography (1→2; 2→4; 4→5; 5→6; 6→7; 7→9; 9→10), the yield of the target product cephalotaxine and its analogs is high, the synthesis cost is reduced, and it is expected to be applied to industrial production.

[0118] 3. The synthesis methods in the prior art mainly construct the chiral nitrogen quaternary carbon center of the molecular structure of Cephalotaxine through chiral resolution and stoichiometric chiral induction (chiral raw materials, chiral reagents); in contrast, the method of the present invention obtains chiral (–)-Cephalotaxine through a metal-catalyzed asymmetric reaction. This method reduces the waste of the other enantiomer in the racemization target molecule and reduces the dependence on stoichiometric chiral sources, and has good chiral economy, which is an advantage of the method of the present invention. DETAILED DESCRIPTION

[0119] The present invention is further described below by specific examples, but the present invention is not limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions.

[0120] Experimental raw materials

[0121]

[0122] Example 1: Preparation of a compound of formula (7) from a compound of formula (1) (step (A))

[0123] The overall preparation route for preparing the enamide compound of formula (7) from the aryl alcohol compound of formula (1) is as follows:

[0124]

[0125] The molecular formula of the arylethanol compound of formula (1) is as follows:

[0126]

[0127] The molecular formulas of the prepared compounds of formula (2), formula (4), formula (5) and formula (6) are listed below:

[0128]

[0129]

[0130] The molecular formula of the compound of formula (7) obtained is as follows:

[0131]

[0132] Example 1-1: Preparation of Compound 7k from Compound 1k

[0133] Dissolve substituted phenylethanol 1k (80.0 g, 481.9 mmol, 1 equivalent) in 500 mL of dichloromethane, add triethylamine (133.9 mL, 963.8 mmol, 2 equivalents) and p-toluenesulfonyl chloride (96.5 g, 506.0 mmol, 1.05 equivalents) in sequence, and stir at room temperature for 6 hours. After TLC monitoring, the raw material completely disappears, 100 mL of water is added, the organic phase is separated, the aqueous phase is extracted 3 times with dichloromethane, and the organic phases are combined. The combined organic phases are washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a light yellow solid 2k (no column chromatography separation and purification is required).

[0134] Under argon atmosphere, NaH (60% dispersed mineral oil) (28.9 g, 722.8 mmol, 1.5 equivalents) was added to a 2L two-necked flask, and 500 mL of drying toluene was added (toluene was in a solvent drying system, using metallic sodium as a drying agent, and heated under reflux to dryness under argon atmosphere), and then a toluene solution of compound 3 (165.5 g, 722.8 mmol, 3.0 M in toluene, 1.5 equivalents) was added dropwise at 0°C. After the addition was complete, the mixture was stirred at 0°C for 30 min, then heated to 100°C and stirred for 1 hour, and the compound of formula (2) (154.0 g, 481.2 mmol, 1 equivalent) was added, and stirring was continued at 100°C for 4 hours. After the raw material completely disappeared as monitored by TLC, the reaction solution was cooled to room temperature, and ice water was slowly added at 0°C to quench the reaction, and the organic phase was separated, and the aqueous phase was extracted 3 times with ethyl acetate, and the organic phases were combined. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure to obtain a white solid 4k (no need for column chromatography separation and purification).

[0135] The white solid 4k (137.8 g, 365.7 mmol, 1 equivalent) was dissolved in 300 mL of tetrahydrofuran, and Et3N·3HF (14.9 mL, 402.2 mmol, 0.5 equivalent) was added, and stirred at 60°C for 5 hours, and the tetrahydrofuran was removed by concentration under reduced pressure, and 100 mL of water was added to precipitate a white solid. The filter cake was first washed with petroleum ether to obtain a white solid 5k (no column chromatography separation and purification was required).

[0136] White solid 5k (5.0 g, 19.0 mmol, 1 equivalent) and IBX (6.38 g, 22.8 mmol, 1.2 equivalent) were mixed, and acetonitrile was added to obtain a mixed solution. The mixed solution was heated to 50°C and kept stirring at this temperature for 3 hours, and then cooled to room temperature. Saturated sodium thiosulfate was added to quench the reaction, the organic phase was separated, and the aqueous phase was extracted 3 times with dichloromethane. The organic phases were combined, washed with saturated sodium carbonate, and then dried over anhydrous sodium sulfate. Then, after reduced pressure concentration, a light yellow oil 6k was obtained (no column chromatography separation and purification was required).

[0137] The above-mentioned light yellow oil 6k was dissolved in 1,2-dichloroethane, indium trichloride (1.2 equivalents) was added, and the system was heated to 60°C. After TLC monitoring that the raw material completely disappeared, it was cooled to room temperature, water was added to quench the reaction, the organic phase was separated, and the aqueous phase was extracted 3 times with dichloromethane. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate; after reduced pressure concentration, recrystallization was performed to obtain a white solid of enamide 7k (no column chromatography separation and purification was required).

[0138] Example 1-2: Preparation of Compounds 7d, 7k-7m from Compounds 1d, 1k-1m

[0139] The preparation process is similar to that of Example 1-1.

[0140] Example 1-3: Preparation of Compounds 7a-7c, 7e-7j from Compounds 1a-1c, 1e-1j

[0141] The preparation process is similar to that of Example 1-1, except for the following two aspects:

[0142] First, the starting material used was replaced by compounds 1a-1c and 1e-1j instead of 1k.

[0143] Secondly, compounds 6a-6c and 6e-6j generated from compounds 1a-1c and 1e-1j were dissolved in 100 mL of dichloromethane, and aluminum chloride (12.6 g, 95.0 mmol, 5 equivalents) was added to the system in batches at 25°C. After TLC monitoring of the complete disappearance of the raw material, a saturated sodium potassium tartrate aqueous solution was added to quench the reaction, the organic phase was separated, and the aqueous phase was extracted 3 times with dichloromethane. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate; after reduced pressure concentration, recrystallization was performed to obtain white solid compounds 7a-7c, 7e-7j (no column chromatography separation and purification was required).

[0144] The total yield and related analysis data of the above 5 stages are as follows:

[0145] Enamide compound 7a of formula (7) (white solid, 29% yield): 1 H NMR (400MHz, CDCl3) δ = 7.22-7.15 (m, 1H), 7.11 (d, J = 7.6Hz, 1H), 7.07 (d, J = 3.8Hz, 2H), 5.61(s,1H),3.87(brs,2H),2.98(s,2H),2.84(t,J=7Hz,2H),2.59(t,J=8.3Hz,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=175.2,140.3,138.1,134.8,129.2,128.9,126.7,125.3,103.1,42.4,35.3,29.0,24.7ppm.IR: 1720,1651,1592,1418,1366,1042,570,557cm -1 .LC-MS(ESI):m / zC 13 H 14 NO[M+H] + Actual value: 200.0.

[0146] Enamide compound 7b of formula (7) (white solid, 38% yield): 1H NMR (400MHz, CDCl3) δ = 7.12 (t, J = 8.0Hz, 1H), 6.73 (d, J = 7.7Hz, 1H), 6.69 (d, J = 8.2Hz, 1H), 5.58 (s ,1H),3.83(brs,2H),3.81(s,3H),3.10(brs,2H),2.83(t,J=7.0Hz,2H),2.58(t,J=8.4Hz,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=175.2,156.2,140.6,136.6,126.9,126.7,121.7,107.5,103.1,55.7,42.6,29.1,24.8,24.7ppm.IR: 2937,1721,1653,1574,1470,1368,1340,1088,883,831,559cm -1 .LC-MS(ESI):m / z C 14 H 16 NO2[M+H] + Actual value: 214.0.

[0147] Enamide compound 7c of formula (7) (white solid, 25% yield): 1 H NMR (400MHz, CDCl3) δ = 7.36 (d, J = 7.5Hz, 1H), 7.07-6.94 (m, 2H), 5.57 (s, 1H), 3 .83(brs,2H),3.26(brs,2H),2.85(t,J=7.2Hz,2H),2.58(t,J=8.4Hz,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=175.1,141.5,137.2,136.8,129.5,128.4,127.7,124.7,102.4,42.3,33.3,28.9,24.8ppm.IR: 2984,1741,1590,1373,1240,1046,937,847,634,607cm -1 .LC-MS(ESI):m / z C 13 H 12 BrNONa[M+Na] + Actual value: 300.0.

[0148] Enamide compound 7d of formula (7) (white solid, 28% yield): 1H NMR (400MHz, CDCl3) δ = 7.01 (d, J = 8.4Hz, 1H), 6.72 (dd, J = 8.4, 2.7Hz, 1H), 6.63 (d, J = 2.6Hz, 1H), 5.54 (s,1H),3.82(brs,2H),3.78(s,3H),2.93(t,J=4.0Hz,2H),2.86-2.74(m,2H),2.61-2.51(m,2H)ppm. 13 CNMR(101MHz, CDCl3)δ=175.1,157.3,139.5,138.1,130.1,127.6,114.9,111.9,102.7,55.2,42.1,35.5,29.1,24.6ppm.IR: 2932,1656,1605,1426,1366,1284,1042,854,570,557cm -1 .LC-MS(ESI):m / z C 14 H 16 NO2[M+H] + Actual value: 230.1.

[0149] Enamide compound 7e of formula (7) (white solid, 14% yield): 1 H NMR (400MHz, CDCl3) δ = 7.10-6.97 (m, 1H), 6.92-6.80 (m, 1H), 6.79 (d, J = 9.2Hz, 1H), 5.5 5(s,1H),3.85(brs,2H),2.93(s,2H),2.82(t,J=7.2Hz,2H),2.57(t,J=8.2Hz,2H)ppm. 13 C NMR (101MHz, CDCl3) 175.1, 160.45 (d, J = 246.3Hz), 140.0 (d, J = 7.3Hz), 139.7 (d, J = 2.0Hz), 131.0 (d, J = 3.3Hz), 1 30.2(d,J=8.0Hz),116.0(d,J=21.7Hz),113.4(d,J=21.3Hz),102.0,42.1,35.2(d,J=1.1Hz),29.0,24.7ppm.IR: 1656,1595,1365,1274,1042,903,672,569,557cm -1 .LC-MS(ESI):m / z C 13 H 13 FNO[M+H] + Actual value: 218.1.

[0150] Enamide compound 7f of formula (7) (white solid, 18% yield): 1 H NMR (400MHz, CDCl3) δ = 7.14 (dd, J = 8.2, 1.9Hz, 1H), 7.08 (s, 1H), 7.02 (d, J = 8.2Hz, 1H), 5 .57(s,1H),3.85(brs,2H),2.94(s,2H),2.85(t,J=6.9Hz,2H),2.60(t,J=8.4Hz,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=175.2,140.9,139.6,133.4,130.4,130.1,129.1,126.7,102.0,42.1,35.1,29.0,24.8ppm.IR: 1723,1646,1592,1426,1363,1171,1122,1042,873,569,557cm - 1 .LC-MS(ESI):m / z C 13 H 13 ClNO[M+H] + Actual value: 234.0.

[0151] 7g of enamide compound of formula (7) (white solid, 13% yield): 1 H NMR (400MHz, CDCl3) δ = 6.94 (d, J = 8.2Hz, 1H), 6.65-6.56 (m, 2H), 5.52 (s, 1H), 3.80 ( brs,2H),3.76(s,3H),2.88(s,2H),2.79(t,J=7.1Hz,2H),2.54(t,J=8.4Hz,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=175.1,158.2,140.7,135.8,130.6,130.1,114.0,110.4,102.8,55.0,42.6,34.3,28.8,24.7ppm.IR: 1720,1652,1602,1428,1363,1159,1041,570,557cm -1 .LC-MS(ESI):m / z C 14 H 16 NO2[M+H] + Actual value: 230.2.

[0152] Enamide compound 7h of formula (7) (white solid, 9% yield): 1 H NMR (400MHz, CDCl3) δ = 6.97 (t, J = 7.9Hz, 1H), 6.78-6.66 (m, 2H), 5.50 (s, 1H), 3.80(brs,2H),2.91(s,2H),2.81(t,J=7.0Hz,2H),2.56(t,J=8.4Hz,2H)ppm. 13 C NMR (101MHz, CDCl3) 175.2, 161.6 (d, J = 244.0Hz), 141.6, 136.8 (d, J = 8.1Hz), 133.8 (d, J = 2.9Hz), 130.5 (d, J =8.4Hz),114.8(d,J=21.7Hz),111.6(d,J=21.3Hz),102.0(d,J=2.1Hz),42.4,34.5,28.8,24.7ppm.IR(KBr): 1719,1650,1603,1430,1369,1042,571,556cm -1 .LC-MS(ESI):m / zC 13 H 13 FNO[M+H] + Actual value: 218.0.

[0153] Enamide compound 7i of formula (7) (white solid, 22% yield): 1 H NMR (400MHz, CDCl3) δ=7.05-7.00(m,1H),6.99-6.92(m,2H),5.46(d,J=1.2Hz ,1H),3.77(brs,2H),2.89(s,2H),2.80(t,J=.8Hz,2H),2.60-2.52(m,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=175.1,141.8,136.6,136.3,132.1,130.4,128.2,124.7,101.6,42.1,34.6,28.8,24.7ppm.IR: 1729,1646,1587,1431,1364,1042,569,557cm -1 .LC-MS(ESI):m / z C 13 H 12 ClNONa[M+Na] + Actual value: 256.0.

[0154] Enamide compound 7j of formula (7) (white solid, 11% yield): 1 H NMR(400MHz, CDCl3)δ=6.84-6.74(m,1H),6.70-6.62(m,1H),5.50(s,1H),3.85(br s,2H),3.84(s,3H),2.86(s,2H),2.81(t,J=6.9Hz,2H),2.56(t,J=8.0Hz,2H)ppm. 13 C NMR (101MHz, CDCl3) δ = 175.3, 151.1, 148.7, 145.8 (d, J = 11.0Hz), 140.3, 131.1 (d, J=5.5Hz),117.0(d,J=18.5Hz),114.0,102.2,56.3,42.6,34.4,29.0,24.8ppm.IR: 1719,1653,1592,1514,1403,1114,1041,768,570,557cm -1 .LC-MS(ESI):m / z C 14 H 14 FNO2Na[M+H] + Actual value: 248.1.

[0155] Enamide compound 7k of formula (7) (white solid, 49% yield): 1 H NMR (400MHz, CDCl3) δ6.58(s,1H),6.57(s,1H),5.91(s,2H),5.47(s,1H),3.80(brs,2H),2.88(s,2H),2.82(t,J=7.5Hz,2H),2.57(t,J=8.5Hz,2H)ppm. 13 C NMR (151MHz, CDCl3) δ175.2,146.3,145.4,139.0,132.1,128.6,109.7,108.8,102.8,100.9,42.9,35.1,29.1,24.8ppm.IR: 2905,1717,1659,1502,1485,1375,1289,1195,1037,938,855,560cm -1 .LC-MS(ESI):m / zC 14 H 14 NO3[M+H] + Actual value: 260.1.

[0156] Enamide compound 71 of formula (7) (white solid, 38% yield): 1 H NMR (400MHz, CDCl3) δ = 6.61 (d, J = 6.4Hz, 2H), 5.47 (s, 1H), 4.24 (s, 4H), 3.81 (brs, 2H), 2.87 (s, 2H), 2.81 (t, J = 6.9Hz, 2H), 2.60-2.54 (m, 2H)ppm. 13 C NMR (151MHz, CDCl3)δ=175.3,141.9,141.1,138.9,131.9,128.4,117.8,117.2,102.6,64.5,64.4,42.6,34.6,29.2,24.7ppm.IR: 1714,1650,1593,1427,1367,1293,1121,1087,1042,1021,569,557cm -1 .LC-MS(ESI):m / zC 15 H 16 NO3[M+H] + Actual value: 285.1.

[0157] Enamide compound 7m of formula (7) (white solid, 31% yield): 1 H NMR (600MHz, CDCl3) δ = 6.98 (d, J = 5.2Hz, 1H), 6.79 (d, J = 5.2Hz, 1H), 5.64 (t, J = 1.5Hz ,1H),3.91(brs,2H),3.08(t,J=4.6Hz,2H),2.82-2.76(m,2H),2.60-2.56(m,2H)ppm; 13 C NMR (150MHz, CDCl3) δ = 175.8, 139.9, 134.3, 133.4, 129.1, 121.7, 98.2, 41.4, 29.4, 29.4, 24.9.ppm; IR: 1700,1436,1255,1076,1042,729cm -1 ; LC-MS (ESI): m / z C 11 H 12 NOS[M+H] + Actual value: 206.1.

[0158] Example 1-4: Preparation of Compound 7n

[0159] Enamide compound 7n can be prepared according to reference (Weinreb, SM et al. J. Am. Chem. Soc. 1975, 97, 2503).

[0160] Example 2: Preparation of compounds of formula (9) and formula (10) from the compound of formula (7) (steps (B) and (C))

[0161] The overall preparation route for preparing the cephalotaxine intermediates of formula (9) and formula (10) and their analogs from the enamide compounds of formula (7) is as follows:

[0162]

[0163] Example 2-1: Preparation of Cephalotaxine Intermediates 9k and 10k from Enamide Compound 7k

[0164] Under argon atmosphere, the enamide 7k (10.0 g, 41.1 mmol, 1 equivalent) obtained from Example 1-1 and the catalyst Rh2(S-PTTL)4 (234 mg, 0.16 mmol, 0.004 equivalent) were placed in a 500 mL Schneider reaction bottle with a magnet, and 150 mL of acetone was added. After the solid raw materials in the reaction bottle were completely dissolved, the compound of formula (8) (31.6 g, 123.3 mmol, 3 equivalents) was added dropwise at a rate of 10 mL / h using a feed pump at 0°C. After the addition was completed and the raw materials completely disappeared as monitored by TLC, 200 mL of petroleum ether was added to the above reaction solution, and a large amount of white solid precipitated in the reaction system. The filter cake was filtered and washed with 100 mL of petroleum ether to obtain 13.9 g of white solid compound 9k (no column chromatography separation and purification was required).

[0165] Compound 9k (13.9 g, 29.6 mmol, 1 equivalent) of formula (9) was dissolved in 100 mL of dimethyl sulfoxide, and NaBr (9.2 g, 88.8 mmol, 3 equivalents) and H2O (1.1 mL, 59.2 mmol, 2 equivalents) were added in sequence, and the mixture was stirred at 100°C for 5 hours. After TLC detected that the raw material completely disappeared, the mixture was cooled to room temperature, 200 mL of dichloromethane was added to dilute the reaction solution, and the organic phase was separated. The organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. The crude product obtained after reduced pressure concentration was dissolved in 50 mL of dichloromethane, and crystallized at room temperature to obtain optically pure cephalotaxine intermediate 10k.

[0166] Example 2-2: Preparation of Cephalotaxine Intermediate Analogs 9a-j, 9l-9m and 10a-10j, 10l-10m from Enamide Compounds 7a-7j, 7l-7m

[0167] According to a process similar to Example 2-1, starting from the enamide compounds 7a-7j and 7l-7m of formula (7), the intermediate analogs of cephalosin 10a-10j and 10l-10m of formula (10) were synthesized in sequence.

[0168] Example 2-3: Preparation of Cephalotaxine Intermediate Analogs 9n and 10n from Enamide Compound 7n

[0169] According to the following process, starting from the enamide compound of formula (7n), the intermediate analogs of cephalosin of formula (9n) and (10n) are synthesized in sequence.

[0170]

[0171] In formula (8), "TBSO-" represents tert-butyldimethylsiloxy ((CH3)3C-Si(CH3)2-O-); in formula (9n), "OTBS-" represents dimethyl tert-butylsilyl ether.

[0172] Under argon atmosphere, enamide 7n (97.3 mg, 0.4 mmol, 1 equivalent) and Rh2(S-PTTL)4 (57.0 mg, 0.004 mmol) were placed in a 10 mL Schneider reaction tube with a magnet, and 2 mL of acetone was added. After all the solid raw materials in the reaction tube were dissolved, the compound of formula (8) (512.8 mg, 2 mmol) was added dropwise at a rate of 1 mL / h using a feed pump at 0°C. After the addition was completed and the raw materials disappeared completely as monitored by TLC, 10 mL of petroleum ether was added to the above reaction solution, and a white solid precipitated in the reaction system. After suction filtration, the filter cake was washed with 10 mL of petroleum ether to obtain a white solid 9n (no column chromatography separation and purification was required).

[0173] Compound 9n (62.1 mg, 0.13 mmol, 1 equivalent) of formula (9r) was dissolved in 5 mL of dimethyl sulfoxide, and NaBr (40.7 mg, 0.39 mmol, 3 equivalents) and H2O (4.7 μL, 0.26 mmol, 2 equivalents) were added in sequence, and the mixture was stirred at 100°C for 2 hours. After TLC detected that the raw material completely disappeared, the mixture was cooled to room temperature, 20 mL of dichloromethane was added to dilute the reaction solution, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. The crude product obtained after reduced pressure concentration was recrystallized to obtain compound 10n of formula (10r).

[0174] The molecular formulas of the prepared cephalotaxine intermediate and analogs of formula (9) are listed below:

[0175]

[0176] The molecular formulas of the prepared cephalotaxine intermediate and analogs of formula (10) are listed below:

[0177]

[0178] The yields and related analytical data of the above two steps (steps (B) and (C)) are as follows:

[0179] Compound 10a of formula (10): Similar to the above overall operation, except that, under argon atmosphere, enamide 7a (79.7 mg, 0.4 mmol) was used to react with compound (8) (512.8 mg, 2.0 mmol) and Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) for 8 h. The solid obtained was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10a (white solid, 80.7 mg, 79% yield, melting point 164-170°C, 86% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.25-7.07 (m, 4H), 4.37-4.19 (m, 1H), 3.63 (t, J = 10.5Hz ,1H),3.18-2.76(m,5H),2.84,2.63(ABq,J=19.1Hz,2H),2.34-2.07(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=215.0,174.1,136.9,135.6,131.6,130.9,128.2,127.0,67.3,53.1,49.5,43.4,35.4,34.9,31.2,29.7ppm.IR: 2919,1739,1685,1596,1410,1036,763cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 17.5 min, t (minor) = 19.8 min. HRMS (ESI-Orbitrap): m / z calculated value C 16 H 18 NO2[M+H] +: 256.1332, actual value: 256.1331.

[0180] Compound 10b of formula (10): Similar to the above overall operation, except that, under argon atmosphere, enamide 7b (91.7 mg, 0.4 mmol) was used to react with compound (8) (512.8 mg, 2.0 mmol) and Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) for 8 h. The solid obtained was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10b (white solid, 77.1 mg, 68% yield, melting point 186-189°C, 86% enantiomeric excess, 1 H NMR (600MHz, CDCl3) δ = 7.12 (t, J = 7.9 Hz, 1H), 6.81 (d, J = 8.2 Hz, 1H), 6.73 (d, J = 7.5 Hz, 1H), 4.20 (dt, J = 14.3, 8.5 Hz, 1H), 3.79 (s, 3H) ,3.69-3.58(m,2H),3.06-2.96(m,1H),2.92-2.73(m,2H),2.87,2.61(ABq,J=19.1Hz,2H),2.58-2.50(m,1H),2.34-2.12(m,4H)ppm. 13 C NMR (151MHz, CDCl3)δ=215.0,174.0,157.9,138.7,127.4,124.1,123.3,110.2,67.2,55.6,53.2,49.5,44.3,35.9,35.6,29.8,22.1ppm.IR: 2919,1741,1684,1582,1465,1411,1265,1087,750cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 19.6 min, t (minor) = 18.8 min. HRMS (ESI-Orbitrap): m / z calculated value C 17 H 20 NO3[M+H] +: 286.1438, Actual value: 286.1437.

[0181] Compound 10c of formula (10): The overall operation is similar to the above, except that, under argon atmosphere, enamide 7c (111.3 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10c (white solid, 91.0 mg, 68% yield, melting point 194-201 ° C, 86% enantiomeric excess, 1 H NMR (600MHz, CDCl3) δ = 7.46 (d, J = 8.0Hz, 1H), 7.05 (d, J = 7.0Hz, 1H), 6.97 (t, J = 7.7Hz, 1H), 4.21-4.09 (m, 1H), 3.70 (dd, J = 11.6, 8.9Hz, 1H),3.59-3.48(m,1H),3.07-2.98(m,1H),2.92-2.74(m,2H),2.72-2.62(m,1H),2.82,2.59(ABq,J=19.3Hz,2H),2.30-2.08(m,4H)ppm. 13 C NMR (151MHz, CDCl3)δ=214.1,173.9,140.0,134.9,132.6,130.2,128.1,126.4,66.6,53.6,48.6,44.2,36.5,35.7,29.9,29.5ppm.IR: 2918,1740,1685,1591,1403,1121,746cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IB-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 21.4 min, t (minor) = 25.0 min. HRMS (ESI-Orbitrap): m / z calculated value C 16 H 17 BrNO2[M+H] + :334.0437, actual value:334.0436.

[0182] Compound 10d of formula (10): Similar to the above overall operation, except that, under argon atmosphere, ene amide 7d (91.7 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10d (white solid, 88.3 mg, 77% yield, melting point 118-125 ° C, 82% enantiomeric excess, 1 H NMR (600MHz, CDCl3) δ = 7.03 (d, J = 7.9Hz, 1H), 6.72-6.65 (m, 2H), 4.34-4.25 (m, 1H), 3.76 (s, 3H), 3.58 (t, J = 10.5Hz, 1H), 3.14 -3.04(m,1H),3.03-2.92(m,2H),2.88-2.73(m,2H),2.81,2.62(ABq,J=18.8Hz,2H),2.34-2.24(m,1H),2.20-2.08(m,3H)ppm. 13 C NMR (151MHz, CDCl3)δ=215.1,174.1,159.3,137.1,131.9,128.9,117.4,111.8,67.6,55.1,52.3,49.6,43.6,35.3,34.7,31.6,29.7ppm.IR: 2923,1740,1680,1603,1416,1042,757,569,557cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 24.8 min, t (minor) = 28.4 min. HRMS (ESI-Orbitrap): m / z calculated value C 17 H 20 NO3[M+H] + :286.1438,actual value:286.1437.

[0183] Compound 10e of formula (10): The overall operation is similar to the above, except that, under argon atmosphere, enamide 7e (86.9 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10e (white solid, 76.2 mg, 70% yield, melting point 212-218 ° C, 80% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.08 (dd, J = 8.0, 5.9Hz, 1H), 6.92-6.80 (m, 2H), 4.36-4.22 (m, 1H), 3.62 (t, J = 10.5Hz, 1H) ,3.16-2.92(m,3H),2.91-2.69(m,2H),2.81,2.63(ABq,J=19.1Hz,2H),2.34-2.24(m,1H),2.21-2.05(m,3H)ppm. 13 C NMR (151MHz, CDCl3) δ = 214.6, 174.0, 162.3 (d, J = 247.3Hz), 138.0 (d, J = 7.7Hz), 132.8 (d, J = 3.1Hz), 132.3 (d ,J=8.0Hz),118.6(d,J=21.7Hz),113.5(d,J=21.0Hz),67.3,52.3,49.5,43.4,35.1,34.7,31.3,29.6ppm.IR: 1741,1683,1589,1496,1409,1238,1152,872,825,753,554cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 16.4 min, t (minor) = 19.1 min. HRMS (ESI-Orbitrap): m / z calculated value C 16 H 17 FNO2[M+H] +: 274.1238, Actual value: 274.1234.

[0184] Compound 10f of formula (10): Similar to the above overall operation, except that, under argon atmosphere, enamide 7f (93.5 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10f (white solid, 86.1 mg, 74% yield, melting point 166-170 ° C, 84% enantiomeric excess, 1 H NMR (600MHz, CDCl3) δ=7.19–7.15(m,2H),7.09–7.02(m,1H),4.37-4.24(m,1H),3.61(dd,J=10.5,1.3Hz,1H),3.15-3.05(m,1H),3.02-2.9 2(m,2H),2.89-2.82(m,1H),2.81(ddd,J=20.0,9.8,1.7Hz,1H),2.85,2.64(ABq,J=19.1Hz,2H),2.35-2.26(m,1H),2.20-2.08(m,3H)ppm. 13 C NMR (151MHz, CDCl3): δ=214.4,174.0,137.6,135.5,133.8,132.2,131.6,127.1,67.3,52.5,49.5,43.3,35.1,34.9,31.1,29.7ppm.IR: 1741,1684,1595,1409,1294,1192,1118,1037,857,753,562cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 14.1 min, t (minor) = 16.3 min. HRMS (ESI-Orbitrap): m / z calculated value C 16 H 17 ClNO2[M+H] +: 290.0942, Actual value: 290.0941.

[0185] Compound 10g of formula (10): Similar to the above overall operation, except that, under argon atmosphere, ene amide 7g (91.7 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10g (white solid, 96.0 mg, 84% yield, melting point 126-130°C, 94% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.06 (d, J = 8.2Hz, 1H), 6.73 (dd, J = 8.2, 2.6Hz, 1H), 6.69 (d, J = 2.5Hz, 1H), 4.32-4.18 (m, 1H ),3.77(s,3H),3.56(t,J=10.4Hz,1H),3.06-2.78(m,5H),2.84,2.62(ABq,J=19.2Hz,2H),2.35-2.09(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=215.0,174.1,158.4,138.3,132.6,127.5,117.6,112.0,67.3,55.2,53.2,49.4,43.4,35.7,35.1,30.3,29.7ppm.IR: 2922,1740,1608,1500,1409,1296,1158,1119,1036,815,750,521cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 22.2 min, t (minor) = 29.4 min. HRMS (ESI-Orbitrap): m / z calculated value C 17 H 20 NO3[M+H] + :286.1438,actual value:286.1436.

[0186] Compound 10h of formula (10): Similar to the above overall operation, except that, under argon atmosphere, ene amide 7h (86.9 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10h (white solid, 24.2 mg, 22% yield, melting point 131-140°C, 94% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.12 (dd, J = 8.2, 6.1Hz, 1H), 6.97-6.83 (m, 2H), 4.36-4.21 (m, 1H), 3.5 9(t,J=10.4Hz,1H),3.10-2.74(m,5H),2.86,2.65(ABq,J=19.1Hz,2H),2.37-2.10(m,4H)ppm. 13 C NMR (151MHz, CDCl3) δ = 214.4, 174.1, 161.6 (d, J = 246.5Hz), 139.2 (d, J = 7.3Hz), 133.1 (d, J = 8.2Hz), 131.4 (d ,J=3.9Hz),117.8(d,J=21.9Hz),114.7(d,J=20.6Hz),67.2,53.1,49.4,43.2,35.5,35.2,30.5,29.7ppm.IR: 3335,3919,1742,1685,1590,1498,1410,1249,1079,1036,872,802,533cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 15.5 min, t (minor) = 20.2 min. HRMS (ESI-Orbitrap): m / z calculated value C 16 H 17 FNO2[M+H] +: 274.1238, Actual value: 274.1235.

[0187] Compound 10i of formula (10): The overall operation is similar to the above, except that, under argon atmosphere, enamide 7i (93.5 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10i (white solid, 75.9 mg, 65% yield, melting point 151-156 ° C, 88% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.17 (dd, J = 8.1, 1.8Hz, 1H), 7.14-7.10 (m, 1H), 7.07 (d, J = 8.0Hz, 1H), 4.31-4.18 ( m,1H),3.57(t,J=10.6Hz,1H),3.10-2.70(m,5H),2.83,2.63(ABq,J=19.1Hz,2H),2.34-2.07(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=214.3,174.0,138.9,134.1,132.9,132.4,130.6,128.0,67.1,52.7,49.3,43.1,35.1,34.9,30.6,29.6ppm.IR: 2921,1741,1685,1595,1406,1119,828,753cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 15.5 min, t (minor) = 20.7 min. HRMS (ESI-Orbitrap): m / z calculated value C 16 H 17 ClNO2[M+H] + :290.0942,actual value:290.0941.

[0188] Compound 10j of formula (10): Similar to the above overall operation, except that, under argon atmosphere, enamide 7j (98.9 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10j (white solid, 81.3 mg, 67% yield, melting point 187-191°C, 92% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 6.84 (d, J = 11.8Hz, 1H), 6.71 (d, J = 8.4Hz, 1H), 4.28-4.15 (m, 1H), 3.83 (s, 3H) ),3.55(t,J=10.0Hz,1H),3.07-2.69(m,5H),2.81,2.59(ABq,J=19.2Hz,2H),2.33-2.05(m,4H)ppm. 13 CNMR (101MHz, CDCl3) δ = 214.5, 174.0, 151.4 (d, J = 247.1Hz), 145.8 (d, J = 10.6Hz), 133.1 (d, J = 3.8Hz), 128.4 (d, J=6.3Hz),119.3(d,J=18.6Hz),116.7(d,J=2.2Hz),67.2,56.5,52.7,49.3,43.4,35.3,35.0,30.3,29.6ppm.IR: 3331,2918,1617,1413,1036,799,611cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 19.1 min, t (minor) = 25.1 min. HRMS (ESI-Orbitrap): m / z calculated value C 17 H 19 FNO3[M+H] +: 304.1343, Actual value: 304.1341.

[0189] Compound 10k of formula (10): The overall operation is similar to the above, except that, under argon atmosphere, enamide 7k (30.0 g, 123.3 mmol), 8 (63.3 g, 2.0 mmol), Rh2(S-PTTL)4 (0.69 g, 0.48 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10k (white solid, 24.9 g, 68% yield, melting point 217-221 ° C, 96% enantiomeric excess, 1H NMR (600MHz, CDCl3) δ = 6.61 (d, J = 1.4Hz, 1H), 5.89 (d, J = 3.5, 1H), 4.28-4.15 (m, 1H), 3.51 (dd, J = 11.2, 9.7Hz, 1H ),3.02-2.78(m,4H),2.73(ddd,J=20.0,9.3,1.7Hz,1H),2.83,2.59(ABq,J=19.0Hz,2H),2.33-2.11(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=214.9,174.2,147.2,146.4,130.4,129.0,111.8,111.1,101.1,67.1,53.0,49.2,43.6,35.7,35.6,31.0,29.7ppm.IR: 2917,1740,1681,1594,1503,1412,1228,1035,931,872,752cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 28.9 min, t (minor) = 36.6 min. HRMS (ESI-Orbitrap): m / z calculated value C 17 H 18 NO4[M+H] + :300.1230, actual value:300.1228.

[0190] For compound 10k of formula (10), according to the above general operation, Rh2(S-PTAD)4 was used as a catalyst to obtain compound 10k of formula (10) with a yield of 65% and an enantiomeric excess of 91%.

[0191] Compound 101 of formula (10): Similar to the above overall operation, except that, under argon atmosphere, enamide 71 (102.9 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 101 (white solid, 100.0 mg, 80% yield, melting point 181-187°C, 91% enantiomeric excess, 1H NMR (400MHz, CDCl3) δ = 6.64 (d, J = 3.0Hz, 2H), 4.32-4.12 (m, 5H), 3.49 (t, J = 10.5H z,1H),3.03-2.71(m,5H),2.84,2.59(ABq,J=19.0Hz,2H),2.35-2.10(m,4H)ppm. 13 C NMR (151MHz, CDCl3)δ=215.1,174.2,142.8,141.8,130.0,128.5,120.3,119.5,67.4,64.3,64.2,52.4,49.5,43.6,35.6,35.0,30.5,29.8ppm.IR: 2925,1740,1682,1583 1503,1299,1067,896,754cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IE-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 50.3 min, t (minor) = 55.0 min. HRMS (ESI-Orbitrap): m / z calculated value C 18 H 20 NO4[M+H] +: 314.1387, Actual value: 314.1386.

[0192] Compound 10m of formula (10): Similar to the above overall operation, except that, under argon atmosphere, enamide 7m (102.9 mg, 0.4 mmol), 8 (512.8 mg, 2.0 mmol), Rh2(S-PTTL)4 (11.4 mg, 0.008 mmol) were used for reaction for 8 h, and the obtained solid was filtered, NaBr and water were added, and heated for decarboxylation to obtain 10m (white solid, 100.0 mg, 34% yield, 75% enantiomeric excess, 1H NMR (400MHz, CDCl3) δ = 7.11 (d, J = 5.1Hz, 1H), 6.79 (d, J = 5.1Hz, 1H), 4.35-4.26 (m, 1H), 3.73 (t, J = 10.0Hz, 1H), 3.46-3.35 (m, 1H), 3.08-3.02 (m, 2 H),2.90(dd,J=19.7,9.9Hz,1H),2.77,2.57(ABq,J=18.6Hz,2H),2.75-2 .65(m,1H),2.48-2.37(m,1H),2.35-2.25(m,1H),2.15-2.03(m,2H)ppm; 13 C NMR (150MHz, CDCl3) δ = 214.3, 173.9, 136.1, 133.9, 130.6, 123.0, 69.9, 50.4, 46.6, 46.5, 36.5, 33.5, 29.9, 27.9ppm; IR: 2371,1684,1592,1413,1126,1055,857cm -1 ; 75% enantiomeric excess measured by chiral HPLC analysis (Daicel Chiralpak IB-3, V 正己烷 / V 2-丙醇 =70:30,ν=1mL / min,λ=237.0nm,t 主要 =20.4min,t 次要 =22.5min); HRMS (ESI-orbital map): calculated m / z: C 14 H 16 NO2S[M+H] + 262.0896, Actual value: 262.0892.

[0193] Compound 10n of formula (10): (white solid, 29.0 mg, 24% yield, melting point 220-225°C, 97% enantiomeric excess, 1H NMR (400MHz, CDCl3) δ = 6.79 (s, 1H), 6.65 (s, 1H), 5.94 (d, J = 4.7Hz, 2H), 3.76 ( t,J=10.2Hz,1H),3.70(d,J=14.2Hz,1H),3.67-3.57(m,1H),3.47-3.39(m,1H ),3.34(d,J=14.2Hz,1H),2.96-2.81(m,1H),2.69(ddd,J=19.4,9.6,1.9Hz,1 H),2.81,2.58(ABq,J=19.0Hz,2H),2.14-2.05(m,2H),1.95-1.71(m,2H)ppm. 13 C NMR (101MHz, CDCl3)δ=213.5,169.1,147.1,147.0,130.4,126.9,111.0,110.7,101.3,67.5,52.3,48.5,47.0,46.2,44.7,41.9,20.6ppm.IR: 2960,2921,1741,1636,1503,1419,1251,1036,925,751cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 40 / 60, 1.0 mL / min, λ = 210 nm, t (major) = 41.0 min, t (minor) = 30.8 min. HRMS (ESI-Orbitrap): m / z calculated value C 17 H 18 NO4[M+H] + 300.1230, Actual value: 300.1228.

[0194] Example 3: Preparation of a compound of formula (11) from a compound of formula (10) (step (D))

[0195] Example 3-1: Preparation of Cephalotaxine Intermediate of Formula (11a) from Cephalotaxine Intermediate Analogue of Formula (10a) analog

[0196] The reaction formula is as follows:

[0197]

[0198] The crystals 10a (1.3 g, 5.0 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (2.1 g, 15.0 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (1.45 g, 5.5 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 5 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 140 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a yellow solid 11a (1.07 g, 68% yield, 86% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 6.86 (m, 2H), 6.35 (m, 2H), 4.23 (d, J = 6.9Hz, 1H), 4. 08-3.92(m,1H),3.92-3.73(m,1H),3.35(d,J=6.1Hz,1H),3.32(s,3H),3. 26(s,3H),3.16-3.07(m,1H),2.52(s,1H),2.59(d,J=13.6Hz,1H),2.42(d dd,J=14.8,6.4,2.2Hz,1H),2.30-2.15(m,4H),2.12(d,J=18.1Hz,1H)ppm. 13 C NMR (101MHz, CDCl3)δ=174.9,125.0,124.8,115.7,115.5,112.0,107.9,100.9,76.5,66.8,59.8,50.2,48.4,39.8,38.4,37.2,31.0,29.0ppm.IR: 2930,1641,1547,1457,1411,1255,1033,742,550cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 8.7 min, t (minor) = 8.9 min. HRMS (ESI-Orbitrap): C 18 H 24 Calculation of m / z of NO4[M+H] + 317.1627, actual value 317.1630.

[0199] Example 3-2: Preparation of Cephalotaxine Intermediate of Formula (11b) from Cephalotaxine Intermediate Analogue of Formula (10b) analog

[0200] The reaction formula is as follows:

[0201]

[0202] The crystals 10b (1.7 g, 5.9 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (2.5 g, 17.7 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (1.71 g, 6.5 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 4 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 140 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a yellow solid 11b (1.08 g, 53% yield, 87% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 6.87 (m, 1H), 6.59 (m, 2H), 4.56 (d, J = 8.2Hz, 1H), 4.12- 3.95(m,1H),3.94-3.72(m,1H),3.52(s,3H),3.37(d,J=6.9Hz,1H),3.34(s,3 H),3.27(s,3H),3.19-3.12(m,1H),2.55(s,1H),2.51(d,J=13.9Hz,1H),2.43 (ddd,J=14.4,6.2,2.2Hz,1H),2.32-2.13(m,4H),2.11(d,J=18.1Hz,1H)ppm. 13 C NMR(101MHz, CDCl3)δ=174.9,145.3,124.3,115.6,115.2,112.4,110.4,107 .5,100.6,76.4,66.9,59.2,50.6,48.2,39.8,38.2,37.4,31.1,29.3ppm.IR: 2930,1641,1547,1457,1411,1255,1033,742,550cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 6.7 min, t (minor) = 8.0 min. HRMS (ESI-Orbitrap): C19 H 26 Calculation of m / z of NO5[M+H] + 347.1733, actual value 347.1738

[0203] Example 3-3: Preparation of Cephalotaxine Intermediate of Formula (11f) from Cephalotaxine Intermediate Analogue of Formula (10f) analog

[0204] The reaction formula is as follows:

[0205]

[0206] The crystals 10f (1.2 g, 4.1 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (1.7 g, 12.3 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (1.19 g, 4.5 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 4 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 130 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a yellow solid 11f (0.83 g, 58% yield, 84% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 6.67 (s, 1H), 6.49 (m, 2H), 4.52 (d, J = 8.2Hz, 1H), 4. 12-3.95(m,1H),3.91-3.74(m,1H),3.33(d,J=6.2Hz,1H),3.32(s,3H),3. 25(s,3H),3.16-3.11(m,1H),2.53(s,1H),2.51(d,J=13.9Hz,1H),2.46(d dd,J=14.8,6.5,2.1Hz,1H),2.36-2.23(m,4H),2.19(d,J=18.0Hz,1H)ppm. 13 C NMR (101MHz, CDCl3)δ=174.9,136.8,122.3,117.6,116.2,112.3,111.4,107.1,100.9,76.1,67.4,50.8,48.8,39.7,38.5,37.6,31.2,29.5ppm.IR: 2933,1645,1540,1357,1451,1205,1032,749,552cm -1Enantiomeric ratio was determined by Daicel Chiralpak IA-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 220 nm, t (major) = 13.7 min, t (minor) = 11.9 min. HRMS (ESI-Orbitrap): C 18 H 23 Calculation of m / z[M+H] for ClNO4 + 351.1237, actual value 351.1239.

[0207] Example 3-4: Preparation of Cephalotaxine Intermediate of Formula (11i) from Cephalotaxine Intermediate Analogue of Formula (10i) analog

[0208] The reaction formula is as follows:

[0209]

[0210] The crystals 10i (1.7 g, 6.0 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (2.9 g, 18.0 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (1.73 g, 6.6 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 4 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 130 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a yellow solid 11i (1.10 g, 52% yield, 89% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 6.66 (s, 1H), 6.44 (m, 2H), 4.51 (d, J = 8.2Hz, 1H), 4. 12-3.95(m,1H),3.92-3.73(m,1H),3.43(d,J=6.2Hz,1H),3.36(s,3H),3. 27(s,3H),3.14-3.10(m,1H),2.52(s,1H),2.51(d,J=13.9Hz,1H),2.41(d dd,J=14.8,6.5,2.1Hz,1H),2.33-2.20(m,4H),2.14(d,J=18.0Hz,1H)ppm. 13C NMR (101MHz, CDCl3)δ=174.7,136.2,121.3,117.5,116.0,112.4,111.6,107.0,100.2,76.5,67.1,50.3,48.4,39.6,38.2,37.5,31.1,29.5ppm.IR: 2934,1643,1541,1358,1451,1202,1033,749,550cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IA-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 220 nm, t (major) = 14.7 min, t (minor) = 12.5 min. HRMS (ESI-Orbitrap): C 18 H 23 Calculation of m / z[M+H] for ClNO4 + 351.1237, actual value 351.1238.

[0211] Example 3-5: Preparation of Cephalotaxine Intermediate of Formula (11k) from Cephalotaxine Intermediate of Formula (10k)

[0212] The reaction formula is as follows:

[0213]

[0214] The crystals 10k (2.0 g, 6.6 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (2.7 g, 19.8 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (1.92 g, 7.3 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 5 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 200 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a light yellow solid 11k (1.31 g, 55% yield, 99% enantiomeric excess, 1H NMR (600MHz, CDCl3) δ = 6.57 (s, 1H), 6.55 (s, 1H), 5.85 (d, J = 2.8Hz, 1H), 4.07 (d, J=6.9Hz,1H),4.04-3.95(m,1H),3.90-3.79(m,1H),3.34(d,J=6.1Hz,1H),3.31 (s,3H),3.28(s,3H),3.16-3.07(m,1H),2.58(s,1H),2.55(d,J=13.6Hz,1H),2. 47(ddd,J=14.8,6.4,2.2Hz,1H),2.18-2.05(m,4H),2.02(d,J=18.1Hz,1H)ppm. 13 C NMR(101MHz, CDCl3)δ=174.9,147.0,146.2,132.7,127.5,112.0,110.9,107 .5,100.9,76.0,66.8,59.8,50.2,48.7,39.2,38.5,37.8,31.0,29.3ppm.IR: 2925,1671,1597,1487,1415,1225,1039,752,558cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 9.7 min, t (minor) = 9.0 min. HRMS (ESI-Orbitrap): C 19 H 24 Calculation of m / z of NO6[M+H] + 362.1598, actual value 362.1599.

[0215] Example 3-5-1: Preparation of Cephalotaxine Intermediate of Formula (11k) from Cephalotaxine Intermediate of Formula (10k) (Replace Oxidants

[0216] The preparation process is similar to that of Example 3-5, except that the base used in Example 3-5 is replaced by potassium hydroxide.

[0217] The yield of the cephalotaxine intermediate of formula (11k) was obtained in 53%.

[0218] Example 3-5-2: Preparation of Cephalotaxine Intermediate of Formula (11k) from Cephalotaxine Intermediate of Formula (10k) (Replace Oxidants

[0219] The preparation process is similar to that of Example 3-5, except that the oxidant used in Example 3-5 is replaced by iodobenzene acetate.

[0220] The yield of the cephalotaxine intermediate of formula (11k) was obtained in 50%.

[0221] Example 3-6: Preparation of Cephalotaxine Intermediate of Formula (111) from Cephalotaxine Intermediate Analogue of Formula (101) analog

[0222] The reaction formula is as follows:

[0223]

[0224] The crystals 101 (1.5 g, 4.7 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (1.9 g, 14.1 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (1.36 g, 5.2 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 4 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 130 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a yellow solid 111 (0.99 g, 56% yield, 90% enantiomeric excess, 1 H NMR (600MHz, CDCl3) δ = 6.67 (s, 1H), 6.58 (s, 1H), 5.85 (t, J = 6.4Hz, 2H), 5.81 (t, J = 6. 4Hz,2H),4.05(d,J=6.8Hz,1H),4.03-3.98(m,1H),3.91-3.77(m,1H),3.32(d,J=6.4H z,1H),3.35(s,3H),3.27(s,3H),3.15-3.07(m,1H),2.55(s,1H),2.52(d,J=13.8Hz,1 H),2.45(ddd,J=14.7,6.3,2.2Hz,1H),2.13-2.06(m,4H),2.00(d,J=18.1Hz,1H)ppm. 13 C NMR(150MHz, CDCl3)δ=175.0,147.3,146.6,133.7,127.8,112.2,110.7,107.4, 100.5,76.3,66.6,66.4,59.2,50.1,48.7,39.5,38.8,37.4,31.1,29.2ppm.IR: 2925,1671,1597,1487,1415,1225,1039,752,558cm -1Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 210 nm, t (major) = 10.7 min, t (minor) = 12.3 min. HRMS (ESI-Orbitrap): C 20 H 26 Calculation of m / z of NO6[M+H] + 376.1682, actual value 376.1685.

[0225] Example 3-7: Preparation of Cephalotaxine Intermediate of Formula (11m) from Cephalotaxine Intermediate Analogue of Formula (10m) analog

[0226] The reaction formula is as follows:

[0227]

[0228] The crystals 10m (0.9 g, 3.4 mmol, 1 equivalent) obtained above were dissolved in 100 mL of solvent (methanol: dichloromethane = 1:1 by volume ratio), potassium carbonate (1.4 g, 10.2 mmol, 3 equivalents) and 2-iodobenzoic acid (IBA) (0.98 g, 3.7 mmol, 1.1 equivalents) were added in sequence, and the reaction was stirred at room temperature for 4 hours. After TLC monitoring of the complete disappearance of the raw material, water was added to quench the reaction, and methanol was removed under reduced pressure. Then 100 mL of dichloromethane was added to dilute, and the organic phase was washed with water and saturated brine in sequence, and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography to obtain a yellow solid 11m (0.55 g, 50% yield, 73% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.32 (d, J = 8.2Hz, 1H), 6.84 (d, J = 8.2Hz, 1H), 4.15 (d, J = 6.8Hz,1H),4.08-3.94(m,1H),3.87-3.67(m,1H),3.38(d,J=6.4Hz,1H),3.36( s,3H),3.27(s,3H),3.18-3.09(m,1H),2.59(s,1H),2.55(d,J=13.8Hz,1H),2. 47(ddd,J=14.8,6.4,2.2Hz,1H),2.15-2.09(m,4H),2.02(d,J=18.1Hz,1H)ppm. 13C NMR (100MHz, CDCl3)δ=174.5,137.7,131.5,126.3,122.7,107.4,101.5,67.6,59.9,50.8,49.7,39.8,38.9,38.4,31.4,29.0ppm.IR: 2912,1641,1527,1457,1405,1212,1025,756,552cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IE-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 220 nm, t (major) = 6.7 min, t (minor) = 8.3 min. HRMS (ESI-Orbitrap): C 16 H 22 Calculation of m / z of NO4S [M+H] + 324.1191, actual value 324.1195.

[0229] Example 4: Preparation of a compound of formula (12) from a compound of formula (11) (step (E))

[0230] Example 4-1: Preparation of a Cephalotaxine Analog of Formula (12a) from a Cephalotaxine Intermediate Analog of Formula (11a)

[0231] The reaction formula is as follows:

[0232]

[0233] Under argon atmosphere, compound 11a (120 mg, 0.38 mmol, 1 equivalent) of formula (11a) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (3.4 mg, 0.004 mmol, 0.01 equivalent) and phenylsilane (116 μl, 0.95 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (71.1 mg, 0.42 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1.5 hours, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (12a) (43.2 mg, 42% yield, 86% enantiomeric excess, 1H NMR (400MHz, CDCl3) δ = 7.12 (m, 1H), 6.74 (m, 2H), 4.93 (s, 1H), 4.77 (d, J = 9.5Hz, 1H), 3.76 (s, 3H), 3.47 (d, J = 9.4Hz, 1H), 3.31-3.29 (m, 1H), 3.10- 3.00(m,1H),2.82(td,J=11.3,7.3,Hz,1H),2.66-2.54(m,2H),2.38(dd, J=14.8,7.2Hz,1H),2.12(dd,J=20.5,9.8Hz,1H),1.95-1.62(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=160.4,136.8,136.0,127.2,127.1,125.5,125.1,97.8,73.6,70.8,57.6,57.0,53.4,48.2,43.2,31.5,20.1ppm.IR: 1590,1466,1412,1221,1121,1089,1031,1020,985,936,550cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 254 nm, t (major) = 10.7 min; t (minor) = 14.5 min HRMS (ESI-Orbitrap): C 17 H 22 Calculation of m / z of NO2[M+H] + 272.1572, actual value 272.1578.

[0234] According to the synthesis route of the present invention, starting from the compound of formula (1a), the (-)-cephalosporin analog product of formula (12a) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 6.5%.

[0235] Example 4-2: Preparation of a Cephalotaxine Analog of Formula (12b) from a Cephalotaxine Intermediate Analog of Formula (11b)

[0236] The reaction formula is as follows:

[0237]

[0238] Under argon atmosphere, compound 11b (270 mg, 0.78 mmol, 1 equivalent) of formula (11b) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (7.0 mg, 0.008 mmol, 0.01 equivalent) and phenylsilane (239 μl, 1.95 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (147.5 mg, 0.85 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1.5 hours, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (12b) (103.3 mg, 4% yield, 86% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.31 (m, 1H), 6.76 (m, 2H), 4.95 (s, 1H), 4.72 (d, J = 9. 5Hz,1H),3.77(s,3H),3.53(s,3H),3.46(d,J=9.3Hz,1H),3.31-3.29(m,1H) ,3.11-3.03(m,1H),2.84(td,J=11.6,7.6,Hz,1H),2.68-2.55(m,2H),2.34( dd,J=14.6,7.0Hz,1H),2.11(dd,J=20.3,9.9Hz,1H),1.93-1.72(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=160.4,147.8,136.2,127.1,125.5,125.1,109.4,97.2,71.6,70.3,57.5,57.2,55.1,53.2,48.0,43.2,31.3,20.0ppm.IR: 1592,1468,1412,1211,1120,1082 1030,1023,989,931,558cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 254 nm, t (major) = 11.7 min; t (minor) = 16.5 min HRMS (ESI-Orbitrap): C 18 H 24 Calculation of m / z of NO3[M+H] + 302.1678, actual value 302.1679.

[0239] According to the synthesis route of the present invention, starting from the compound of formula (1b), the (-)-cephalosporin analog product of formula (12b) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 6.0%.

[0240] Example 4-3: Preparation of a Cephalotaxine Analog of Formula (12f) from a Cephalotaxine Intermediate Analog of Formula (11f)

[0241] The reaction formula is as follows:

[0242]

[0243] Under argon atmosphere, compound 11f (184 mg, 0.52 mmol, 1 equivalent) of formula (11f) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (4.7 mg, 0.005 mmol, 0.01 equivalent) and phenylsilane (159 μl, 1.3 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (98.4 mg, 0.57 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1 hour, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (12f) (85.7 mg, 54% yield, 84% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.22 (s, 1H), 6.76 (m, 2H), 4.89 (s, 1H), 4.70 (d, J = 9.8Hz, 1H), 3.68 (s, 3H), 3.44 (d, J = 9.5Hz, 1H), 3.33-3.28 (m, 1H), 3.12- 3.08(m,1H),2.85(td,J=11.9,7.8,Hz,1H),2.67-2.58(m,2H),2.39(dd, J=14.6,7.0Hz,1H),2.16(dd,J=20.8,9.6Hz,1H),1.95-1.74(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=160.4,137.2,133.5,133.0,127.5,125.8,125.1,97.6,71.4,70.2,57.9,55.0,53.0,48.5,43.0,31.2,20.0ppm.IR: 1592,1465,1410,1219,1125,1080,1028,1020,983,930,550cm -1Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 254 nm, t (major) = 12.1 min; t (minor) = 14.2 min HRMS (ESI-Orbitrap): C 17 H 21 Calculation of m / z[M+H] for ClNO2 + 306.1183, actual value 306.1185.

[0244] According to the synthesis route of the present invention, starting from the compound of formula (1f), the (-)-cephalosporin analog product of formula (12f) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 4.2%.

[0245] Example 4-4: Preparation of a Cephalotaxine Analog of Formula (12i) from a Cephalotaxine Intermediate Analog of Formula (11i)

[0246] The reaction formula is as follows:

[0247]

[0248] Under argon atmosphere, compound 11i (217 mg, 0.62 mmol, 1 equivalent) of formula (11i) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (5.6 mg, 0.006 mmol, 0.01 equivalent) and phenylsilane (190 μl, 1.6 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (117 mg, 0.68 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1 hour, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (12i) (104 mg, 55% yield, 84% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.24 (s, 1H), 6.77 (m, 2H), 4.85 (s, 1H), 4.71 (d, J = 9.8Hz, 1H), 3.64 (s, 3H), 3.45 (d, J = 9.6Hz, 1H), 3.30-3.25 (m, 1H), 3.15- 3.07(m,1H),2.83(td,J=11.6,7.8,Hz,1H),2.66-2.56(m,2H),2.36(dd, J=14.8,7.2Hz,1H),2.15(dd,J=20.4,9.4Hz,1H),1.96-1.75(m,4H)ppm. 13C NMR (101MHz, CDCl3)δ=160.5,137.3,133.5,133.1,127.5,125.4,125.1,97.4,71.3,70.1,57.6,55.2,53.1,48.6,432,31.4,20.1ppm.IR: 1592,1455,1414,1215,1135,1086,1022,973,932,551cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 254 nm, t (major) = 12.9 min; t (minor) = 14.0 min HRMS (ESI-Orbitrap): C 17 H 21 Calculation of m / z[M+H] for ClNO2 + 306.1183, actual value 306.1184.

[0249] According to the synthesis route of the present invention, starting from the compound of formula (1i), the (-)-cephalosporin analog product of formula (12i) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 3.9%.

[0250] Example 4-5: Preparation of (-)-cephalotaxine of formula (12k) from cephalotaxine intermediate of formula (11k)

[0251] The reaction formula is as follows:

[0252]

[0253] Under argon atmosphere, compound 11k (572.2 mg, 1.58 mmol, 1 equivalent) of formula (11k) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (14.5 mg, 0.015 mmol, 0.01 equivalent) and phenylsilane (485 μl, 3.95 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (299 mg, 1.73 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1 hour, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (12k) (234 mg, 47% yield, 99% enantiomeric excess, 1H NMR(600MHz, CDCl3)δ=6.68(s,1H),6.65(s,1H),5.90(s,2H),4.92(s,1H), 4.75(d,J=9.2Hz,1H),3.73(s,3H),3.67(d,J=9.4Hz,1H),3.41-3.31(m,1H) ,3.13-3.02(m,1H),2.92(td,J=11.3,7.3,Hz,1H),2.65-2.53(m,2H),2.36( dd,J=14.5,7.0Hz,1H),2.02(dd,J=21.5,9.8Hz,1H),1.94-1.67(m,4H)ppm. 13 C NMR (101MHz, CDCl3)δ=160.4,146.8,146.0,134.2,128.0,112.5,110.2,100.8,97.5,73.2,70.5,57.9,57.1,53.8,48.5,43.5,31.6,20.2ppm.IR: 1591,1486,1418,1221,1120,1087,1041,1020,986,930,557cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 292 nm, t (main) = 14.7 min; HRMS (ESI-Orbitrap): C 18 H 22 Calculation of m / z of NO4[M+H] + 316.1543, actual value 316.1540.

[0254] According to the synthesis route of the present invention, starting from the compound of formula (1k), the (-)-cephalotaxine product of formula (12k) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 8.6%.

[0255] Example 4-6: Preparation of Cephalotaxine Analogs of Formula (121) from Cephalotaxine Intermediate Analogs of Formula (111)

[0256] The reaction formula is as follows:

[0257]

[0258] Under argon atmosphere, compound 111 of formula (111) (900 mg, 2.4 mmol, 1 equivalent) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (22.0 mg, 0.002 mmol, 0.01 equivalent) and phenylsilane (736 μl, 6.0 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (454 mg, 2.6 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1.5 hours, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (121) (386 mg, 49% yield, 90% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 6.67 (s, 1H), 6.62 (s, 1H), 5.92 (t, J = 9.5, 2H), 5.91 (t, J = 9. 5,2H),4.92(s,1H),4.75(d,J=9.2Hz,1H),3.73(s,3H),3.67(d,J=9.4Hz,1H),3.41 -3.31(m,1H),3.15-3.08(m,1H),2.92(td,J=11.8,7.7,Hz,1H),2.68-2.57(m,2H) ,2.35(dd,J=14.2,7.7Hz,1H),2.02(dd,J=20.5,9.6Hz,1H),1.97-1.64(m,4H)ppm. 13 C NMR(101MHz, CDCl3)δ=160.5,145.8,145.6,134.2,128.0,112.5,110.2,100 .8,97.5,73.0,70.1,64.3,64.2,57.4,53.6,48.4,43.6,31.5,20.1ppm.IR: 1581,1496,1438,1225,1122,1088,1042,1021,986,933,557cm -1 Enantiomeric ratio was determined by Daicel Chiralpak IG-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 290 nm, t (major) = 17.2 min, t (minor) = 21.5 min; HRMS (ESI-Orbitrap): C 19 H 24 Calculation of m / z of NO4[M+H] + 330.1627, actual value 330.1629.

[0259] According to the synthesis route of the present invention, starting from the compound of formula (11), the (-)-cephalosporin analog product of formula (121) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 8.3%.

[0260] Example 4-7: Preparation of Cephalotaxine Analogs of Formula (12m) from Cephalotaxine Intermediate Analogs of Formula (11m)

[0261] The reaction formula is as follows:

[0262]

[0263] Under argon atmosphere, compound 11m of formula (11m) (430 mg, 1.3 mmol, 1 equivalent) was dissolved in tetrahydrofuran, RhH(CO)(PPh3)3 (12.2 mg, 0.001 mmol, 0.01 equivalent) and phenylsilane (398 μl, 3.2 mmol, 2.5 equivalent) were added in sequence, and the mixture was stirred at room temperature for 2 hours. Anhydrous p-toluenesulfonic acid (246 mg, 1.4 mmol, 1.1 equivalent) was then added to the reaction system, and the mixture was stirred at 70°C for 1 hour, cooled to room temperature, saturated sodium bicarbonate was added to quench the reaction, and the solvent was dried by spin drying. The crude product was purified by alkaline alumina (eluent: EtOAc) to obtain a white foamy compound of formula (12m) (187 mg, 52% yield, 73% enantiomeric excess, 1 H NMR (400MHz, CDCl3) δ = 7.43 (d, J = 8.2Hz, 1H), 7.00 (d, J = 8.2Hz, 1H), 4.96 (s, 1 H),4.79(d,J=9.2Hz,1H),3.75(s,3H),3.64(d,J=9.8Hz,1H),3.44-3.32(m,1 H),3.18-3.04(m,1H),2.95(td,J=11.8,7.7,Hz,1H),2.70-2.58(m,2H),2.36 (dd,J=14.8,7.8Hz,1H),2.06(dd,J=18.5,9.8Hz,1H),1.99-1.65(m,4H)ppm. 13 C NMR (100MHz, CDCl3)δ=160.5,137.5,131.1,126.8,122.5,97.6,79.2,73.9,59.8,49.3,39.2,38.5,38.1,31.3,29.1ppm.IR: 2910,1651,1520,1437,1400,1210,1024,759,550cm -1Enantiomeric ratio was determined by Daicel Chiralpak IE-3 (25 cm), i-PrOH / n-hexane = 30 / 70, 1.0 mL / min, λ = 220 nm, t (major) = 9.4 min, t (minor) = 10.3 min. HRMS (ESI-Orbitrap): C 15 H 20 Calculation of m / z of NO2S [M+H] + 278.1136,actual value 278.1138.

[0264] According to the synthesis route of the present invention, starting from the compound of formula (1m), the (-)-cephalosporin analog product of formula (12m) is synthesized with the longest linear step of 9 steps and 2 column chromatography, and the total yield of the product is 6.0%.

Claims

1. A method for synthesizing chiral (-)-cephalotaxine, characterized in that: The steps include: Step (A): firstly synthesizing an ene amide compound of formula (7); Step (B): then reacting the enamide compound of formula (7) with the enol diazoacetate compound of formula (8) to obtain the cephalotaxine intermediate of formula (9); Then, the compound of formula (10) is prepared by the decarboxylation reaction of step (C), The oxidation reaction in step (D) yields a compound of formula (11), and the amide reduction and methanol removal reaction of step (E) to obtain chiral (-)-cephalotaxine; the structure of the chiral (-)-cephalotaxine is shown in formula (12): Wherein, in step (B), in a solvent, under the action of a catalyst, the enamide compound of formula (7) and the enol diazoacetate compound of formula (8) are reacted as follows: Wherein, n is 1; X is carbon; Among them, R 1 , R 2 , R 3 and R 4 are the same or different and are each independently selected from the following groups: hydrogen, amino, hydroxy, mercapto, cyano, nitro, halogen, benzyl, C6-C 14 Aryl or heteroaryl, unsubstituted, singly substituted or polysubstituted C1-C 18 Alkyl, unsubstituted, singly or polysubstituted, C1-C 18 Alkoxy; wherein the substituted substituent is selected from: amino, hydroxyl, mercapto, cyano, nitro, halogen or trihalomethyl, and the halogen refers to fluorine, chlorine, bromine or iodine; Or, R 2 ,R 3 It can also exist in a state of forming a heterocyclic ring with an adjacent group, and the heterocyclic ring is selected from the following: Among them, R 6 , R 7 and R 8 Each is independently a C1-C4 alkyl group, a C1-C4 alkoxy group or a halogenated C1-C4 alkyl group, wherein the C1-C4 alkyl group is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, and the halogenated C1-C4 alkyl group is selected from chloromethyl; Among them, R 9 is C1-C4 alkyl, benzyl or phenyl; the C1-C4 alkyl is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; Wherein, the catalyst is selected from Rh2(S-PTA)4, Rh2(S-PTV)4, Rh2(S-PTPA)4, Rh2(S-PTPG)4, Rh2(S-PTTL)4, Rh2(S-PTAD)4, Rh2(S-TCPTTL)4, Rh2(S-BPTTL)4, Rh2(S-NTTL)4, Rh2(S-DOSP)4, Rh2(S-MSP)4, Rh2(S-MEPY)4 or Rh2(R-BTPUCP)4; Wherein, in step (B), the solvent is selected from one or more of aromatic hydrocarbon solvents, ester solvents, ether solvents, ketone solvents, alkane solvents and halogenated solvents; Wherein, in step (B), the reaction temperature is -30°C to 50°C.

2. The method for synthesizing chiral (-)-cephalotaxine according to claim 1, characterized in that: Selected from trimethylsilyl, triethylsilyl, ethyldimethylsilyl, tert-butyldimethylsilyl or diethylmethylsilyl.

3. The method for synthesizing chiral (-)-cephalotaxine according to claim 1, characterized in that: In step (C), the cephalosporin intermediate of formula (9) is subjected to a decarboxylation reaction as shown below in a solvent in the presence of a metal halide and water to obtain a cephalosporin intermediate of formula (10); Among them, n, X, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 The meaning expressed is the same as that in claim 1; Wherein, the metal halide salt is selected from lithium chloride, sodium chloride, potassium chloride, lithium bromide, sodium bromide, potassium bromide, lithium iodide, sodium iodide or potassium iodide.

4. The method for synthesizing chiral (-)-cephalotaxine according to claim 1, characterized in that: In step (D), the cephalosporin intermediate of formula (10) is subjected to an oxidation reaction as shown below in a solvent in the presence of an oxidant and a base to obtain the cephalosporin intermediate of formula (11); Wherein, Me represents a methyl group; n, X, R 1 , R 2 , R 3 and R 4 The meaning expressed is the same as that in claim 1; Wherein, the oxidant is selected from iodobenzene acetate, iodobenzene trifluoroacetate, iodobenzoylbenzene, 2-iodobenzoic acid, 5-chloro-2-iodobenzoic acid, 5-methoxy-2-iodobenzoic acid, 5-nitro-2-iodobenzoic acid, or 4,5-dimethoxy-2-iodobenzoic acid; Wherein, the alkali is selected from potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate or potassium phosphate.

5. The method for synthesizing chiral (-)-cephalotaxine according to claim 1, characterized in that: In step (E), in tetrahydrofuran solvent, in the presence of a catalyst and silane, the amide in the cephalotaxine intermediate of formula (11) is reduced by reacting at room temperature, and then p-toluenesulfonic acid is added and heated to reflux, and methanol is removed to obtain chiral (-)-cephalotaxine of formula (12); Wherein, the catalyst is selected from RhH(CO)(PPh3)3, Karstedt catalyst, Vaska catalyst, H2PtCl6·6H2O, Ti(O i Pr)4, Mo(CO)6, NiCl2 or RuHCl(CO)(PPh3)3; Wherein, the silane is selected from 1,1,3,3-tetramethyldisiloxane (TMDS), polymethylhydrogensiloxane (PMHS), diethylsilane, triethylsilane, phenylsilane, diphenylsilane, diphenylmethylsilane or triethoxysilane.

6. The method for synthesizing chiral (-)-cephalotaxine according to claim 1, characterized in that: In step (A), in a solvent, under the action of a base, a compound of formula (2) and a compound of formula (3) are reacted as shown below to obtain a compound of formula (4); Among them, n, X, R 1 , R 2 , R 3 and R 4 The meaning expressed is the same as that in claim 1; Wherein, R is a leaving group, and the leaving group is a halogen or a sulfonate group; the halogen is selected from chlorine, bromine or iodine; the sulfonate group is selected from methanesulfonate, p-toluenesulfonate, benzenesulfonate or trifluoromethanesulfonate; Among them, R 5 is benzyl, silyl or acyl; the silyl is selected from tert-butyldimethylsilyl, triethylsilyl, methyldiphenylsilyl, triisopropylsilyl, triphenylsilyl, dimethylphenylsilyl, triethoxysilyl or tert-butyldiphenylsilyl; the acyl is selected from acetyl or benzoyl; Wherein, the base is selected from sodium hydride, potassium hydride, potassium tert-butoxide, sodium tert-butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, or potassium hexamethyldisilazide; and the reaction temperature is 50°C-120°C.

7. The method for synthesizing chiral (-)-cephalotaxine according to claim 6, characterized in that: In step (A), the following steps are further included: In a solvent, the compound of formula (4) is removed by removing R 5 Protecting group to obtain a compound of formula (5); Among them, n, X, R 1 , R 2 , R 3 and R 4 The meaning indicated is the same as that in claim 1; R 5 The meaning expressed is the same as that in claim 6; Among them, when R 5 When it is benzyl, the removal reaction is carried out under 1 atm H2 atmosphere at room temperature with methanol as solvent and Pd / C as removal reagent; Among them, when R 5 When it is silicon-based, hydrofluoric acid, fluorosilicic acid, triethylamine trihydrofluoride, tetrabutylammonium fluoride hydrate, potassium bifluoride and ammonium fluoride are used as removal agents, tetrahydrofuran or acetonitrile is used as solvent, and the reaction temperature is 25-65°C; Among them, when R 5 When it is an acyl group, potassium carbonate is used as a removing agent, methanol is used as a solvent, and the reaction temperature is room temperature.

8. The method for synthesizing chiral (-)-cephalotaxine according to claim 7, characterized in that: In step (A), the following steps are further included: in a solvent, under the action of an oxidant, oxidizing the compound of formula (5) to obtain a compound of formula (6); Among them, n, X, R 1 , R 2 , R 3 and R 4 The meaning expressed is the same as that in claim 1; Wherein, the oxidant is selected from 2-iodobenzoic acid (IBX), Dess-Martin periodinane (DMP), pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), Swern oxidant, Pfitzner & Moffatt oxidant, Parrikh & Doering oxidant, or Albright & Goldman oxidant.

9. The method for synthesizing chiral (-)-cephalotaxine according to claim 8, characterized in that: In step (A), the following step is further included: in a solvent, under the action of Lewis acid, the compound of formula (6) is subjected to a ring-closing reaction as shown below to obtain an enamide compound of formula (7): Wherein, the Lewis acid is selected from tin tetrachloride, aluminum trichloride, or indium trichloride; and the reaction temperature is 0°C-100°C.

Citation Information

Cited By

  • Synthesis method of compound with cephalotaxine tetracyclic skeleton

    CN120665078A